👪

Inheritance

1

Autosomal dominant inheritance HP:0000006

Disease results from a single heterozygous ZMIZ1 allele. The great majority of reported variants arose de novo, but vertical transmission is established: a father and his two sons all carry the same pathogenic frameshift allele c.1310delC (p.Pro437ArgfsX84). Expressivity within that family was markedly variable — severity of intellectual disability and eyelid ptosis differed between affected members and only one of the two children had sensorineural hearing loss — so a mildly affected transmitting parent can easily be missed without targeted parental testing.

Autosomal dominant inheritance Expressivity: VARIABLE

Show evidence (3 references)

PMID:35432459 SUPPORT Human Clinical

"NEDDFSA is caused by heterozygous pathogenic variants in the ZMIZ1 gene on chromosome 10q22.3 with autosomal dominant (AD) mode of inheritance."

States the mode of inheritance and the heterozygous, single-allele mechanism for the named entity NEDDFSA.

PMID:31833199 SUPPORT Human Clinical

"we report on a father and his two sons demonstrating autosomal dominant inheritance of a novel pathogenic ZMIZ1 variant, c.1310delC (p.Pro437ArgfsX84), causing this recently described neurodevelopmental syndrome."

Documents germline transmission across two generations, confirming dominant inheritance rather than exclusively de novo occurrence.

PMID:31833199 SUPPORT Human Clinical

"Our report demonstrates that phenotypic features of ZMIZ1-related neurodevelopmental syndrome are variable even within the same family and that parental testing to identify a mildly affected parent is needed."

Supports the variable-expressivity classification and the clinical implication that transmitting parents may be only mildly affected.

?

Discussions and Knowledge Gaps

3

What is the natural history of NEDDFSA across the lifespan, and what surveillance schedule should ZMIZ1-related disorder actually follow?

KNOWLEDGE GAP OPEN neddfsa_no_management_guideline

Attached to

pathophysiology#Global Neurodevelopmental Impairment

No GeneReviews chapter, consensus management statement, natural-history study, or registered clinical trial exists for this disorder. The management framework recorded in this entry is standard-of-care extrapolation from the phenotype list, not evidence-based guidance, and is deliberately left without evidence items for that reason. The single published adult (a woman who died unexpectedly at 52 and had chronic pain and lower limb deformities) is currently the only window onto adult outcome, so even basic questions — does hearing loss progress, does the hip and foot pathology need surveillance, is there excess mortality — are unanswered.

Proposed experiments

Prospective international ZMIZ1 natural-history registry

exp_neddfsa_prospective_registry

Assemble a prospective international ZMIZ1 registry with standardized developmental, ophthalmological, audiological, orthopaedic, cardiac, and renal assessment at fixed ages, powered to produce an evidence-based surveillance schedule and a natural-history curve extending into adulthood.

Systematic HPO re-phenotyping of all published cases

exp_neddfsa_hpo_rephenotyping

Systematically re-code every published ZMIZ1 case against HPO from the primary descriptions, replacing the current mixture of narrative descriptions and partially overlapping literature reviews with computable, denominator-anchored feature frequencies.

Do all pathogenic ZMIZ1 alleles act by loss of coactivator function, or do some act by dominant-negative or gain-of-function mechanisms?

KNOWLEDGE GAP OPEN neddfsa_allele_mechanism_direction

Attached to

pathophysiology#Heterozygous ZMIZ1 Variant pathophysiology#Impaired PIAS-Family Coactivator Function

The functional data point in opposite directions depending on the allele. An alanine-rich in-frame deletion (p.Val288_Ala293del) reduced ZMIZ1 protein abundance, consistent with haploinsufficiency, while a nearby alanine-rich missense allele (p.Ala304Pro) increased ZMIZ1 mRNA and protein and mislocalized the protein, which is not a loss-of-dosage phenotype. Gene-level constraint (loss-of-function observed/expected 0.13) supports dosage sensitivity but says nothing about individual missense alleles. The in vivo evidence that established pathogenicity used overexpression of mutant alleles by in utero electroporation, a paradigm that cannot separate loss of function from dominant-negative action. Resolving this matters directly for therapeutic strategy: dosage restoration would help only the haploinsufficient alleles.

Proposed experiments

Isogenic heterozygous knock-in iPSC allele series

exp_neddfsa_isogenic_ipsc_allele_series

Generate isogenic heterozygous knock-in human iPSC lines for representative alleles from each domain (TPR, alanine-rich, proline-rich, SP-RING/MIZ, transactivation) alongside a heterozygous null, differentiate to cortical neurons, and compare transcriptomes. Null-like profiles indicate loss of function; profiles diverging from the null indicate dominant-negative or gain-of-function action.

Endogenous-level coactivation and SUMO ligase assays per allele class

exp_neddfsa_endogenous_coactivation_assays

Assay NOTCH1 and androgen receptor coactivation and SUMO E3 ligase activity for each allele class at endogenous expression levels rather than by overexpression, so that direction of effect is not an artifact of the assay.

Is the craniofacial and distal skeletal phenotype that names this disorder actually caused by ZMIZ1 loss in skeletal tissue, given that the only in vivo model deletes Zmiz1 exclusively in forebrain and therefore cannot develop it?

HUMAN MODEL MISMATCH OPEN neddfsa_skeletal_arm_unmodeled

Attached to

pathophysiology#Disrupted Craniofacial and Distal Skeletal Patterning

The mechanism chain for the neurological arm is well supported in vivo, but the arm that gives the disorder its name is not modeled at all. The forebrain-specific Zmiz1 conditional knockout by construction cannot produce craniofacial or limb skeletal phenotypes, and the in utero electroporation model is CNS-only. The single functional study in a non-neural cell type used human skeletal muscle cells, which are neither the cartilage nor the osteoblast lineage that patterns the distal skeleton, and it reported increased proliferation and migration — a direction of effect that is not obviously connected to the clinical skeletal findings. This is a genuine model-to-human validity gap rather than an absence of evidence, which is why the Disrupted Craniofacial and Distal Skeletal Patterning node is marked PROVISIONAL.

Proposed experiments

Neural-crest and limb-mesenchyme conditional Zmiz1 knockouts

exp_neddfsa_crest_and_limb_conditional_ko

Generate a cranial-neural-crest-specific and a limb-mesenchyme-specific Zmiz1 conditional knockout and phenotype the craniofacial skeleton and autopod for the anomalies reported in patients, establishing whether the skeletal arm is cell-autonomous to those lineages.

ZMIZ1 target profiling in human iPSC-derived crest and limb mesenchyme

exp_neddfsa_crest_target_profiling

Profile ZMIZ1 chromatin occupancy and NOTCH1/SMAD target-gene output in human iPSC-derived cranial neural crest cells and limb-bud-like mesenchyme carrying patient alleles, to identify the skeletal target genes that are currently unknown.

⚙

Pathophysiology

7

Heterozygous ZMIZ1 Variant

A single heterozygous variant in ZMIZ1 (10q22.3) is the initiating lesion. Reported alleles are overwhelmingly de novo and are distributed across the coding sequence but cluster in functionally defined regions: the N-terminal tetratricopeptide repeat (TPR) that mediates NOTCH1 binding, the central intrinsically disordered alanine-rich motif, the proline-rich domains, the SP-RING/MIZ zinc finger, and the C-terminal transactivation domain. Both missense substitutions and frameshifting truncations occur, and structural lesions (balanced translocations disrupting ZMIZ1 or its regulatory region) have also been reported. ZMIZ1 is strongly constrained against loss-of-function variation in population data, consistent with dosage sensitivity. Functional consequences documented so far are nonetheless heterogeneous: an alanine-rich in-frame deletion reduced mutant protein abundance, whereas a different alanine-rich missense allele increased ZMIZ1 expression and mislocalized the protein, so a simple haploinsufficiency model does not account for every allele. The latter measurement comes from transfected constructs in skeletal muscle and HEK293T cells rather than endogenous patient cells, so it more plausibly reports altered protein stability than patient-level upregulation.

ZMIZ1 hgnc:16493

Downstream

Impaired PIAS-Family Coactivator Function Variants in the domains that mediate partner binding, SUMO E3 ligase activity, and transactivation directly degrade ZMIZ1 coregulator function.

Show evidence (5 references)

PMID:30639322 SUPPORT Human Clinical

"Of these 19, 14 unrelated subjects carried de novo heterozygous single-nucleotide variants (SNVs) or single-base insertions/deletions, 3 siblings harbored a heterozygous single-base insertion, and 2 subjects had a balanced translocation disrupting ZMIZ1 or involving a regulatory region of ZMIZ1."

Establishes the heterozygous, largely de novo allelic architecture and the existence of structural as well as point lesions.

PMID:30639322 SUPPORT Human Clinical

"In total, we identified 13 point mutations that affect key protein regions, including a SUMO acceptor site, a central disordered alanine-rich motif, a proline-rich domain, and a transactivation domain."

Localizes the pathogenic point mutations to the functional regions that carry ZMIZ1 coregulator activity.

PMID:38686122 SUPPORT Computational

"Zmiz1 has an oe-score of 0.13 for loss-of-function mutations (observed SNVs 7/expected SNVs 52.1), which indicates that only 13% of the expected loss-of-function variants were observed in sampled data."

Population-genetic constraint metric supporting dosage sensitivity of ZMIZ1. Classified COMPUTATIONAL because it is derived from a variant-database observed/expected calculation, not a wet-lab assay.

+ 2 more references

Impaired PIAS-Family Coactivator Function

ZMIZ1 is a PIAS-family transcriptional coregulator built around a conserved MIZ (Msx-interacting zinc finger) SP-RING domain that confers SUMO E3 ligase activity, an N-terminal TPR that binds NOTCH1, and a C-terminal transactivation domain. It does not bind DNA on its own; it potentiates signal-dependent transcription factors — NOTCH1, the androgen receptor, p53, and SMAD3/4 — and works with the BAF (SWI/SNF) chromatin remodeling complex. Pathogenic variants degrade this coactivation function. The best-characterized readout is androgen receptor coactivation, which is measurably impaired in vitro by patient alleles; a newly described interaction with the general transcription factor GTF2I and dysregulation of TGF-beta1 pathway genes suggest the coregulator hub is broader than the four classical partners.

Notch signaling pathway GO:0007219 ⚠ ABNORMAL androgen receptor signaling pathway GO:0030521 ↓ DECREASED protein sumoylation GO:0016925 chromatin remodeling GO:0006338 ⚠ ABNORMAL

transcription coactivator activity GO:0003713 ↓ DECREASED SUMO E3 ligase activity GO:0019789

Downstream

Dysregulated Developmental Transcriptional Programs Loss of coactivator potency at NOTCH1, AR, p53, and SMAD3/4 target promoters changes the output of the transcriptional programs those pathways drive.

Show evidence (6 references)

PMID:30639322 SUPPORT Other

"ZMIZ1 is a coactivator of several transcription factors, including p53, the androgen receptor, and NOTCH1."

Establishes the coactivator identity and names the three classical transcription-factor partners on which the mechanism turns.

PMID:30639322 SUPPORT In Vitro

"In vitro, ZMIZ1 showed impaired coactivation of the androgen receptor."

Direct functional demonstration that patient variants degrade ZMIZ1 coactivation, the central molecular claim of this node.

PMID:35670836 SUPPORT Other

"Among other interacting domains, they possess a MIZ (Msx-interacting zinc finger) that relates them to members of the protein inhibitor of activated STAT (PIAS) family and provides them the capacity to function as SUMO E3 ligases."

Sources the PIAS-family assignment and the SUMO E3 ligase activity carried by the MIZ/SP-RING domain. Classified OTHER because the source is a narrative expert review rather than primary data.

+ 3 more references

Dysregulated Developmental Transcriptional Programs

ZMIZ1 is most highly expressed during embryonic brain development in both mouse and human and is enriched in cortex, hippocampus, and cerebellum — the regions most implicated in intellectual disability and autism. Loss of ZMIZ1 function changes the transcriptional programs governing neurogenesis, neuronal differentiation, and synaptic signaling. In a forebrain-specific Zmiz1 knockout mouse, ZMIZ1 was shown by RNA-seq and ChIP-seq to regulate key neurodevelopmental effectors including Lhx2, Auts2, and EfnB2, and the ZMIZ1 interaction network is enriched for autism-associated genes. Because the same coactivator serves NOTCH1, AR, p53, and SMAD3/4 in non-neural tissue, the same lesion perturbs craniofacial, skeletal, cardiac, and genitourinary developmental programs, which is why the disorder is syndromic rather than purely neurological.

regulation of transcription by RNA polymerase II GO:0006357 ⚠ ABNORMAL neurogenesis GO:0022008 ⚠ ABNORMAL skeletal system development GO:0001501 ⚠ ABNORMAL ephrin receptor signaling pathway GO:0048013 ↓ DECREASED

Downstream

Impaired Cortical Neurogenesis, Neuronal Differentiation, and Positioning The neural arm of the transcriptional dysregulation, expressed in cortical progenitors and their projection-neuron progeny.

Disrupted Craniofacial and Distal Skeletal Patterning The non-neural arm. ZMIZ1 is broadly expressed in embryonic tissues and partners with SMAD3/4 and NOTCH1, both central to skeletal and craniofacial morphogenesis, but the specific target genes that produce the human facial and distal limb phenotype have not been identified.

Show evidence (4 references)

PMID:38686122 SUPPORT Other

"Zmiz1 is highly expressed during embryonic brain development in mice and humans, and though broadly expressed across the brain, Zmiz1 is enriched in areas prominently impacted in ID and ASD such as cortex, hippocampus, and cerebellum."

Establishes the developmental timing and regional enrichment that make ZMIZ1 loss a developmental-transcription problem. Classified OTHER because the statement is derived from mining public expression atlases spanning both mouse and human, not from an experiment performed in an animal model.

PMID:38686122 SUPPORT Model Organism

"Our analysis reveals that Zmiz1 regulates multiple developmental processes, including neurogenesis, neuron connectivity, and synaptic signaling."

Names the specific developmental programs under ZMIZ1 transcriptional control.

PMID:41633496 SUPPORT Model Organism

"We identified Zmiz1-mediated downstream regulation of key neurodevelopmental genes, including Lhx2, Auts2, and EfnB2."

Identifies the specific transcriptional targets through which ZMIZ1 loss is transmitted to cortical development.

+ 1 more reference

Impaired Cortical Neurogenesis, Neuronal Differentiation, and Positioning

The cellular consequence in the developing cortex, comprising reduced progenitor output, impaired neuronal differentiation and dendritic outgrowth, and abnormal neuronal positioning. The two mouse paradigms disagree on the positioning component and that disagreement is curated explicitly rather than smoothed over. In utero electroporation of patient ZMIZ1 mutant alleles into cortical progenitors produced abnormal pyramidal neuron morphology, polarization, and positioning, with mispositioned neurons accumulating in the ventricular, subventricular, and intermediate zones and depleted from the upper cortical plate. The complementary forebrain-specific Zmiz1 knockout reproduced cortical microcephaly, corpus callosum dysgenesis, and abnormal differentiation of upper-layer neurons, but its BrdU birthdating showed the surviving neurons were correctly positioned, so in that model microcephaly arises from reduced progenitor proliferation and neurogenesis rather than from a migration defect. The likeliest reconciliation is that the positioning phenotype is specific to the overexpression paradigm (see the neddfsa_allele_mechanism_direction discussion); note, however, that the human data independently support a positioning abnormality — cortical heterotopias were found at autopsy in one adult and on MRI in a majority of imaged patients. The dendritic outgrowth deficit in the knockout is rescued by reactivating the ephrin-B2 pathway, identifying a specific and in principle tractable effector arm; transcriptomically the same model disrupts synaptic-signaling gene programs.

cortical pyramidal (projection) neuron CL:0000598 cortical neural progenitor cell CL:0011020

regulation of neurogenesis GO:0050767 ↓ DECREASED neuron migration GO:0001764 ⚠ ABNORMAL neuron differentiation GO:0030182 ⚠ ABNORMAL dendrite development GO:0016358 ↓ DECREASED cerebral cortex development GO:0021987 ⚠ ABNORMAL corpus callosum development GO:0022038 ⚠ ABNORMAL synaptic signaling GO:0099536 ⚠ ABNORMAL

Downstream

Global Neurodevelopmental Impairment Miswired and mispositioned cortical circuitry is the substrate of the cognitive, language, motor, and behavioral phenotype.

Show evidence (6 references)

PMID:30639322 SUPPORT Model Organism

"In vivo, overexpression of ZMIZ1 mutant alleles in developing mouse brains using in utero electroporation resulted in abnormal pyramidal neuron morphology, polarization, and positioning, underscoring the importance of ZMIZ1 in neural development"

Directly links patient alleles to abnormal pyramidal neuron morphology and positioning in vivo.

PMID:35432459 SUPPORT Model Organism

"resulted in impaired neuronal positioning with an accumulation in the ventricular and subventricular zones (VZ/SVZ) and intermediate zone (IZ) and a corresponding depletion in the upper cortical plate (CP)"

Specifies the laminar distribution of the positioning defect in the overexpression paradigm — retention in the proliferative and intermediate zones with depletion of the upper cortical plate. This is a secondary description of the PMID:30639322 experiment, quoted from the cached full text of PMID:35432459.

PMID:41633496 REFUTE Model Organism

"Despite reduced numbers, BrdU+ neurons were correctly positioned according to their birthdates, indicating that migration was not disrupted"

Directly refutes the migration/positioning component of this node in the endogenous loss-of-function model: BrdU birthdating showed correct laminar positioning, so the microcephaly in that model reflects reduced progenitor proliferation and neurogenesis, not mispositioning. Curated as REFUTE so the contradiction with the overexpression paradigm is visible rather than averaged away.

+ 3 more references

Disrupted Craniofacial and Distal Skeletal Patterning

The non-neural developmental arm that gives the syndrome its name. ZMIZ1 is expressed broadly in embryonic tissues beyond brain — including limb-forming mesoderm, heart, and kidney — and coactivates NOTCH1 and SMAD3/4, both central to craniofacial and appendicular skeletal morphogenesis. The clinical result is a recognizable dysmorphic facial pattern together with distal skeletal anomalies of the hands and feet, joint hypermobility, and hip dysplasia; prenatally the same program failure can present as short femur with intrauterine growth restriction. The specific ZMIZ1 target genes responsible have not been identified, and no skeletal-tissue model of the disorder exists, so this node is provisional relative to the well-worked cortical arm. The one direct functional study in a non-neural cell type (human skeletal muscle cells) showed a patient allele altering proliferation and migration and dysregulating TGF-beta1 pathway genes, which is suggestive but is muscle rather than cartilage or bone.

skeletal muscle cell CL:0000188

skeletal system development GO:0001501 ⚠ ABNORMAL transforming growth factor beta receptor signaling pathway GO:0007179 ⚠ ABNORMAL

Downstream

Syndromic Multisystem Malformation Disrupted craniofacial and appendicular patterning is expressed at the level of the whole organism as the recognizable dysmorphic and skeletal syndrome, alongside the cardiac and genitourinary malformations that share the same coactivator-dependent developmental programs.

Show evidence (3 references)

PMID:35432459 SUPPORT Human Clinical

"Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NEDDFSA) is a rare syndromic disorder characterized by global neurodevelopmental delay, early-onset hypotonia, poor overall growth, poor speech/language ability, and additional common phenotypes such as eye..."

Establishes that distal skeletal anomalies of the hands and feet and joint hypermobility are core, defining features requiring a non-neural developmental arm.

PMID:41918386 SUPPORT Human Clinical

"Combined with 25 cases from the literature, the main manifestations of patients have included intellectual disability, growth retardation and cranio-limb skeletal dysplasia, albeit without clear genotype-phenotype correlation."

Confirms cranio-limb skeletal dysplasia as a recurrent manifestation across the published series, and notes the absence of a genotype-phenotype correlation.

PMID:41354990 SUPPORT In Vitro

"Functional assays demonstrated enhanced proliferation and migration in HSkMCs expressing the mutant ZMIZ1."

The only functional evidence for a ZMIZ1 patient allele acting in a non-neural musculoskeletal cell type. Marked PARTIAL because skeletal muscle cells are not the cartilage or bone lineage that patterns the distal skeleton.

Syndromic Multisystem Malformation

The organism-level structural output that makes this disorder syndromic rather than a pure neurodevelopmental disorder: the recognizable dysmorphic facial pattern, distal skeletal anomalies of the hands and feet, joint hypermobility or contracture, and the minority cardiac and genitourinary malformations. Prenatally the same failure can present as microcephaly with short femur and intrauterine growth restriction. Because no lineage-specific model exists, this node inherits the PROVISIONAL standing of its upstream patterning node.

Show evidence (2 references)

PMID:30639322 SUPPORT Human Clinical

"The associated features include growth failure, feeding difficulties, microcephaly, facial dysmorphism, and various other congenital malformations."

Establishes that congenital malformations beyond the nervous system are part of the syndrome, which is what this organism-level node collects.

PMID:41354990 SUPPORT Human Clinical

"supplementary shared characteristics including joint hypermobility or joint contracture, eye anomalies, and acral skeletal malformations of extremities"

Names the non-neurological element of the syndrome — including that joint involvement runs in both directions, hypermobility or contracture — in the source's own words.

Global Neurodevelopmental Impairment

The organism-level neurodevelopmental output: early hypotonia and feeding difficulty, then delayed motor milestones, poor language acquisition, intellectual disability of highly variable severity, and behavioral abnormalities including autism and ADHD. Severity is not predictable from the variant. A domain-resolved re-analysis of 36 published individuals found that alanine-rich-domain variants associate preferentially with intellectual disability and motor delay while TPR and proline-rich-domain variants associate more with autism plus intellectual disability, but a prenatally-ascertained series explicitly found no clear genotype-phenotype correlation, and the intrafamilial variability in the one multigenerational family shows that genotype alone does not fix outcome.

Show evidence (3 references)

PMID:35432459 SUPPORT Human Clinical

"global neurodevelopmental delay, early-onset hypotonia, poor overall growth, poor speech/language ability"

Names the core organism-level neurodevelopmental features in the source's own words.

PMID:40529245 SUPPORT Human Clinical

"We find that patients with SNVs in the Alanine-rich domain show strong association with diagnosis of ID (62.5%), motor delay (70%), and other physical phenotypic manifestations (100%), while ASD diagnosis in combination with ID is more strongly associated with mutations in TPR and Proline-rich domains."

Supports the domain-resolved phenotype tendencies described in this node.

PMID:41918386 SUPPORT Human Clinical

"the main manifestations of patients have included intellectual disability, growth retardation and cranio-limb skeletal dysplasia, albeit without clear genotype-phenotype correlation"

Supports the core manifestations while qualifying the domain-association sub-claim: an independent literature synthesis found no clear genotype-phenotype correlation, so the domain-phenotype tendencies must not be used prognostically. Marked PARTIAL rather than REFUTE because it qualifies one statement inside this node, it does not contradict the node itself.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

35

Cardiovascular 1

Congenital Heart Disease Abnormal heart morphology HP:0001627

Show evidence (2 references)

PMID:38117436 SUPPORT Human Clinical

"The patient was a 6-month-old male infant who exhibited dysmorphic facial features, neurodevelopmental abnormalities, congenital heart disease, and previously unreported genitourinary system anomalies."

Documents congenital heart disease in a ZMIZ1-only proband.

PMID:41039966 SUPPORT Human Clinical

"craniofacial dysmorphisms, genitourinary anomalies, cardiac defects, lower limb deformities, and chronic pain"

Independent documentation of cardiac defects in a second ZMIZ1-only individual.

Digestive 1

Feeding Difficulties HP:0011968

Show evidence (1 reference)

PMID:30639322 SUPPORT Human Clinical

"The associated features include growth failure, feeding difficulties, microcephaly, facial dysmorphism, and various other congenital malformations."

Names feeding difficulties among the associated features.

Ear 1

Sensorineural Hearing Loss FREQUENT Sensorineural hearing impairment HP:0000407

Show evidence (2 references)

PMID:40529245 SUPPORT Human Clinical

"Thirty-three percent of patients presented hearing loss and 14% presented sleep abnormalities."

Hearing loss in 33 percent of the subseries maps to the FREQUENT band (30-79%).

PMID:31833199 SUPPORT Human Clinical

"While they all show syndromic findings along with short stature and intellectual disability, only one child had sensorineural hearing loss."

Specifies the hearing loss as sensorineural and documents its intrafamilial variability.

Eye 3

Ptosis FREQUENT HP:0000508

Show evidence (2 references)

PMID:39658964 SUPPORT Human Clinical

"The most common ophthalmic finding was ptosis (35%)."

Quantitative literature-review frequency of 35 percent maps to the FREQUENT band (30-79%).

PMID:31833199 SUPPORT Human Clinical

"Moreover, severity of intellectual disability and eyelid ptosis were variable among the affected members."

Independent documentation of ptosis and of its intrafamilial severity variability.

Myopia OCCASIONAL HP:0000545

Show evidence (2 references)

PMID:39658964 SUPPORT Human Clinical

"Refractive error was common (myopia in 20%, hyperopia in 12%)."

Myopia in 20 percent of cases maps to the OCCASIONAL band (5-29%).

PMID:41039966 SUPPORT Human Clinical

"a woman with a de novo ZMIZ1 c.899C>T (p.Thr300Met) variant, low average IQ, high myopia"

Independent documentation of myopia, at the severe end.

Strabismus OCCASIONAL HP:0000486

Show evidence (1 reference)

PMID:39658964 SUPPORT Human Clinical

"Other findings included strabismus (12%) and amblyopia (16%)."

Strabismus in 12 percent of cases maps to the OCCASIONAL band (5-29%).

Genitourinary 2

Genitourinary Anomalies Abnormality of the genitourinary system HP:0000119

Show evidence (2 references)

PMID:38117436 SUPPORT Human Clinical

"congenital heart disease, and previously unreported genitourinary system anomalies"

First report of genitourinary anomalies in this disorder.

PMID:41039966 SUPPORT Human Clinical

"craniofacial dysmorphisms, genitourinary anomalies, cardiac defects, lower limb deformities, and chronic pain"

Independent confirmation in a second individual, establishing this as a recurrent rather than isolated finding.

Cryptorchidism HP:0000028

Show evidence (1 reference)

PMID:39658964 SUPPORT Human Clinical

"telecanthus, downward palpebral slants, myopia, cryptorchidism, hallux valgus and developmental delay"

Documents cryptorchidism in the index case. Frequency omitted because it is a single-case observation in a male patient.

Head and Neck 3

Microcephaly FREQUENT HP:0000252

Show evidence (3 references)

PMID:30639322 SUPPORT Human Clinical

"The associated features include growth failure, feeding difficulties, microcephaly, facial dysmorphism, and various other congenital malformations."

Names microcephaly among the associated features in the delineating cohort.

PMID:40529245 SUPPORT Human Clinical

"The most common morphological abnormality was microcephaly (64%)"

Quantitative basis for the FREQUENT band (30-79%) among imaged individuals.

PMID:41633496 SUPPORT Model Organism

"Loss of ZMIZ1 led to cortical microcephaly, corpus callosum dysgenesis, and abnormal differentiation of upper-layer cortical neurons."

Model-organism corroboration that ZMIZ1 loss is sufficient to cause cortical microcephaly.

Facial Dysmorphism FREQUENT Abnormal facial shape HP:0001999

Show evidence (3 references)

PMID:30639322 SUPPORT Human Clinical

"The associated features include growth failure, feeding difficulties, microcephaly, facial dysmorphism, and various other congenital malformations."

Names facial dysmorphism among the associated features.

PMID:40529245 SUPPORT Human Clinical

"ID, speech delay, motor delay, and facial dysmorphism are the most frequently observed neurodevelopmental and physical phenotypic manifestations in patients with ZMIZ1 mutations"

Supports the FREQUENT band. The paper's per-domain facial-dysmorphism rates are 100% (alanine-rich), 78% (proline-rich), and 40% (TPR), which pool below the 80% VERY_FREQUENT floor, so FREQUENT is the defensible band.

PMID:40529245 SUPPORT Human Clinical

"Morphological alterations in the brain and cranium are highly prevalent in individuals with missense mutations in ZMIZ1, without any association to specific protein domains."

Sources the absence of a domain association. Marked PARTIAL because in the source this sentence refers to brain and cranial imaging/head-circumference findings, not to facial gestalt, so it does not by itself quantify facial dysmorphism.

Downslanted Palpebral Fissures HP:0000494

Show evidence (1 reference)

PMID:39658964 SUPPORT Human Clinical

"bilateral congenital ptosis and blepharophimosis, floppy eyelids, telecanthus, downward palpebral slants, myopia, cryptorchidism, hallux valgus and developmental delay"

Documents downward palpebral slants in the index case. Frequency omitted — the review quantified only ptosis, refractive error, strabismus, and amblyopia.

Musculoskeletal 4

Hypotonia FREQUENT HP:0001252

Show evidence (2 references)

PMID:35432459 SUPPORT Human Clinical

"global neurodevelopmental delay, early-onset hypotonia, poor overall growth, poor speech/language ability"

Names early-onset hypotonia among the characterizing features of the entity.

PMID:40529245 SUPPORT Human Clinical

"Of the individuals with variants affecting the Alanine-rich domain, 100% presented facial dysmorphism, 100% presented distal skeletal abnormalities, 71% presented growth abnormalities, and 57% presented hypotonia and visual abnormalities"

Quantitative basis for the FREQUENT band (30-79%). The figure is for the alanine-rich-domain subgroup of the domain-resolved subseries, not the whole published cohort.

Joint Hypermobility FREQUENT HP:0001382

Show evidence (1 reference)

PMID:35432459 SUPPORT Human Clinical

"additional common phenotypes such as eye anomalies, joint hypermobility, and skeletal anomalies of the hands and feet"

Names joint hypermobility explicitly as a common phenotype of the disorder.

Joint Contracture HP:0034392

Show evidence (2 references)

PMID:41354990 SUPPORT Human Clinical

"supplementary shared characteristics including joint hypermobility or joint contracture, eye anomalies, and acral skeletal malformations of extremities"

Establishes contracture as a recognized part of the NEDDFSA joint phenotype, not merely the opposite of the curated hypermobility.

PMID:41354990 SUPPORT Human Clinical

"bilateral auricular deformity (Fig. 1b), bilateral hand contractures (Fig. 1c–e), congenital vertical talus (Fig. 1f), developmental delay, hearing impairment, and bilateral cryptorchidism"

Documents bilateral hand contractures in an individual proband. Frequency omitted because this is a single case.

Hip Dysplasia HP:0001385

Show evidence (1 reference)

PMID:35432459 SUPPORT Human Clinical

"a 5-year-old girl with mild development delay, mild intellectual disability, bilateral hip dysplasia, joint hypermobility, amblyopia in both eyes, strabismus in the right eye, and dysmorphic facial features"

Documents bilateral hip dysplasia in an individual case. Frequency omitted because this is a single-case observation.

Nervous System 10

Global Developmental Delay VERY_FREQUENT HP:0001263

Show evidence (2 references)

PMID:35432459 SUPPORT Human Clinical

"Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NEDDFSA) is a rare syndromic disorder characterized by global neurodevelopmental delay"

Global neurodevelopmental delay is named as a defining, characterizing feature of the entity, supporting the VERY_FREQUENT band.

PMID:30639322 SUPPORT Human Clinical

"Here, we report 19 subjects with intellectual disability and developmental delay carrying variants in ZMIZ1."

All 19 subjects in the founding cohort had intellectual disability and developmental delay, corroborating near-universal occurrence.

Intellectual Disability FREQUENT HP:0001249

Show evidence (3 references)

PMID:40529245 SUPPORT Human Clinical

"Human genetic studies have linked loss-of-function variants in Zinc Finger MIZ-Type Containing 1 (ZMIZ1) to a spectrum of neurodevelopmental disorders (NDDs), such as intellectual disability (ID), autism spectrum disorders (ASD), and attention-deficit/hyperactivity disorder (ADHD)."

Establishes intellectual disability as a core ZMIZ1-associated neurodevelopmental outcome.

PMID:31833199 SUPPORT Human Clinical

"Moreover, severity of intellectual disability and eyelid ptosis were variable among the affected members."

Direct support for the variable-severity statement, from a family sharing one allele.

PMID:41039966 SUPPORT Human Clinical

"Here we report a woman with a de novo ZMIZ1 c.899C>T (p.Thr300Met) variant, low average IQ"

Documents the mild end of the cognitive spectrum, supporting the FREQUENT rather than VERY_FREQUENT band for frank intellectual disability.

Delayed Speech and Language Development FREQUENT HP:0000750

Show evidence (2 references)

PMID:35432459 SUPPORT Human Clinical

"global neurodevelopmental delay, early-onset hypotonia, poor overall growth, poor speech/language ability"

Poor speech and language ability is named as a characterizing feature of the syndrome, alongside the other core neurodevelopmental features.

PMID:40529245 SUPPORT Human Clinical

"The percentage of individuals with variants associated with ID and speech delay was high in all domains"

Quantitative support that speech delay is frequent regardless of which ZMIZ1 domain is affected, justifying the FREQUENT band.

Motor Delay FREQUENT HP:0001270

Show evidence (1 reference)

PMID:40529245 SUPPORT Human Clinical

"patients with SNVs in the Alanine-rich domain show strong association with diagnosis of ID (62.5%), motor delay (70%), and other physical phenotypic manifestations (100%)"

Provides the quantitative motor-delay rate underpinning the FREQUENT frequency band.

Behavioral Abnormalities Atypical behavior HP:0000708

Show evidence (1 reference)

PMID:31833199 SUPPORT Human Clinical

"the primary phenotypic features include intellectual disability/developmental delay, seizures, hearing loss, behavioral issues, failure to thrive, and various congenital malformations"

Lists behavioral issues among the primary phenotypic features of the syndrome.

Autism Spectrum Disorder FREQUENT HP:0000717

Show evidence (3 references)

PMID:40529245 SUPPORT Human Clinical

"while ASD diagnosis in combination with ID is more strongly associated with mutations in TPR and Proline-rich domains"

Supports both the occurrence of autism in this disorder and the domain-preference statement.

PMID:40529245 SUPPORT Human Clinical

"the percent of individuals with variants in TPR and Proline-rich diagnosed with ASD (60 and 66%, respectively)"

Supplies the quantitative basis for the FREQUENT band (30-79%). The same subseries reports 14% for alanine-rich-domain variants, so the rate is strongly domain-dependent and these figures come from a neurodevelopmentally ascertained literature sample rather than a population cohort.

PMID:41633496 SUPPORT Model Organism

"Zmiz1-knockout mice showed alterations in motor activity, anxiety, communication, and social interactions with strong sex differences, resembling phenotypes associated with autism."

Model-organism corroboration of the autism phenotype. Kept distinct from the human clinical evidence by evidence_source.

Attention Deficit Hyperactivity Disorder OCCASIONAL HP:0007018

Show evidence (1 reference)

PMID:40529245 SUPPORT Human Clinical

"ADHD and the presence of seizures are phenotypes with weaker association with variants in these domains (less than 30% of individuals)."

Gives the quantitative ceiling (under 30 percent) supporting the OCCASIONAL band.

Seizures OCCASIONAL HP:0001250

Show evidence (2 references)

PMID:31833199 SUPPORT Human Clinical

"the primary phenotypic features include intellectual disability/developmental delay, seizures, hearing loss, behavioral issues, failure to thrive, and various congenital malformations"

Lists seizures among the primary features of the syndrome.

PMID:40529245 SUPPORT Human Clinical

"ADHD and the presence of seizures are phenotypes with weaker association with variants in these domains (less than 30% of individuals)."

Quantifies seizures as a minority feature, justifying OCCASIONAL rather than FREQUENT.

Abnormal Corpus Callosum Morphology OCCASIONAL HP:0001273

Show evidence (3 references)

PMID:41633496 SUPPORT Other

"Abnormalities in the CC and midline structures have been reported in patients with ZMIZ1 mutations"

Establishes that callosal abnormality is a human finding in this disorder, not only a mouse-model observation. Classified OTHER, not HUMAN_CLINICAL: this is a background sentence in a mouse study summarizing other authors' patients, so the citing publication generated no human data. The quantitative human figure is the PMID:40529245 item below.

PMID:40529245 SUPPORT Human Clinical

"Abnormalities in the corpus callosum, with or without heterotopias near the ventricular space, were observed in 21% of individuals"

Quantitative basis for the OCCASIONAL band (5-29%), with MRI-examined individuals as the denominator.

PMID:41633496 SUPPORT Model Organism

"Loss of ZMIZ1 led to cortical microcephaly, corpus callosum dysgenesis, and abnormal differentiation of upper-layer cortical neurons."

Model-organism corroboration that ZMIZ1 loss is sufficient to produce callosal dysgenesis.

Sleep Disturbance OCCASIONAL HP:0002360

Show evidence (1 reference)

PMID:40529245 SUPPORT Human Clinical

"Thirty-three percent of patients presented hearing loss and 14% presented sleep abnormalities."

Sleep abnormalities in 14% of the subseries maps to the OCCASIONAL band (5-29%).

Growth 3

Failure to Thrive HP:0001508

Show evidence (2 references)

PMID:30639322 SUPPORT Human Clinical

"The associated features include growth failure, feeding difficulties, microcephaly, facial dysmorphism, and various other congenital malformations."

Names growth failure among the associated features.

PMID:31833199 SUPPORT Human Clinical

"the primary phenotypic features include intellectual disability/developmental delay, seizures, hearing loss, behavioral issues, failure to thrive, and various congenital malformations"

Lists failure to thrive among the primary phenotypic features.

Short Stature HP:0004322

Show evidence (1 reference)

PMID:31833199 SUPPORT Human Clinical

"While they all show syndromic findings along with short stature and intellectual disability, only one child had sensorineural hearing loss."

Documents short stature in all three affected family members. Frequency omitted: three relatives sharing a single allele is not a basis for a population band.

Intrauterine Growth Restriction Intrauterine growth retardation HP:0001511

Show evidence (1 reference)

PMID:41918386 SUPPORT Human Clinical

"At 30 weeks of gestation, the fetus was found to have microcephaly, short femur and intrauterine growth restriction."

Single prenatal case. Frequency omitted because prenatal ascertainment of this disorder is reported only once.

Other 7

Gray Matter Heterotopia FREQUENT HP:0002282

Show evidence (2 references)

PMID:40529245 SUPPORT Human Clinical

"Fifty-seven percent of MRI-examined individuals presented abnormalities in the cortex, such as heterotopias in the cortical white matter and near the ventricles"

Quantitative basis for the FREQUENT band (30-79%). Denominator is MRI-examined individuals, not all reported patients.

PMID:41039966 SUPPORT Human Clinical

"Additional findings seen on autopsy included cerebral cortical neuronal heterotopias."

Neuropathological confirmation at autopsy, complementing the imaging-based frequency above.

Telecanthus HP:0000506

Show evidence (1 reference)

PMID:39658964 SUPPORT Human Clinical

"bilateral congenital ptosis and blepharophimosis, floppy eyelids, telecanthus, downward palpebral slants, myopia, cryptorchidism, hallux valgus and developmental delay"

Documents telecanthus in the index case. Frequency omitted for the same reason as the other unquantified periocular features.

Blepharophimosis HP:0000581

Show evidence (1 reference)

PMID:39658964 SUPPORT Human Clinical

"a pediatric patient presenting with multiple anomalies including bilateral congenital ptosis and blepharophimosis"

Documents blepharophimosis. Frequency omitted because the paper describes it as a previously undescribed feature seen in one patient.

Amblyopia OCCASIONAL HP:0000646

Show evidence (1 reference)

PMID:39658964 SUPPORT Human Clinical

"Other findings included strabismus (12%) and amblyopia (16%)."

Amblyopia in 16 percent of cases maps to the OCCASIONAL band (5-29%).

Distal Skeletal Anomalies of the Hands and Feet FREQUENT Abnormal digit morphology HP:0011297

Show evidence (2 references)

PMID:35432459 SUPPORT Human Clinical

"additional common phenotypes such as eye anomalies, joint hypermobility, and skeletal anomalies of the hands and feet"

Names skeletal anomalies of the hands and feet as a common, characterizing phenotype of the entity.

PMID:41918386 SUPPORT Human Clinical

"the main manifestations of patients have included intellectual disability, growth retardation and cranio-limb skeletal dysplasia"

Corroborates limb skeletal dysplasia as a main manifestation across the published series.

Hallux Valgus HP:0001822

Show evidence (1 reference)

PMID:39658964 SUPPORT Human Clinical

"telecanthus, downward palpebral slants, myopia, cryptorchidism, hallux valgus and developmental delay"

Documents hallux valgus. Frequency omitted — reported in individual cases rather than quantified across the series.

Hirschsprung Disease Aganglionic megacolon HP:0002251

Show evidence (1 reference)

PMID:38686122 SUPPORT Other

"a case study revealed a de novo pathogenic variant in ZMIZ1 in a patient with developmental delay and Hirschsprung Disease"

Marked PARTIAL, and classified OTHER rather than HUMAN_CLINICAL, because this is a background sentence in a non-clinical study relaying a single primary case from another group (Valind et al. 2021, J Pediatr Surg Case Rep 71:101889, doi:10.1016/j.epsc.2021.101889). That primary report is not PubMed-indexed and has no retrievable abstract, so the claim could not be verified at source. Frequency omitted.

🧬

Genetic Associations

1

ZMIZ1 (Heterozygous ZMIZ1 variants are the sole established cause of NEDDFSA. The gene lies at 10q22.3, spans 21 exons, and encodes a 1067-amino-acid PIAS-family transcriptional coactivator. Most pathogenic alleles arise de novo; germline transmission from a mildly affected parent is documented. ZMIZ1 is highly constrained against loss of function in population data (observed/expected 0.13).)

Gene: ZMIZ1 hgnc:16493 relationship_type: CAUSATIVE variant_origin: DE_NOVO

Show evidence (6 references)

PMID:30639322 SUPPORT Human Clinical

"Here, we report 19 subjects with intellectual disability and developmental delay carrying variants in ZMIZ1."

The founding cohort establishing ZMIZ1 as the causative gene for this syndromic neurodevelopmental disorder.

PMID:38117436 SUPPORT Human Clinical

"The zinc finger MIZ-type containing 1 gene (ZMIZ1) is a causative gene of NEDDFSA that encodes a protein inhibitor of the activated STAT-like family transcriptional regulator."

Independent confirmation of causation and of the PIAS-like protein family assignment.

PMID:38686122 SUPPORT Computational

"Zmiz1 has an oe-score of 0.13 for loss-of-function mutations (observed SNVs 7/expected SNVs 52.1), which indicates that only 13% of the expected loss-of-function variants were observed in sampled data."

Quantifies the loss-of-function constraint cited in the association text.

+ 3 more references

🔬

Variants

5

NM_020338.4:c.1310delC (p.Pro437ArgfsX84) Pathogenic

Gene: ZMIZ1 hgnc:16493

Frameshifting single-base deletion in a proline-rich region, the first ZMIZ1 allele shown to be transmitted vertically — carried by an affected father and both of his affected sons.

Show evidence (1 reference)

PMID:31833199 SUPPORT Human Clinical

"a novel pathogenic ZMIZ1 variant, c.1310delC (p.Pro437ArgfsX84), causing this recently described neurodevelopmental syndrome"

Names the allele and its pathogenic classification.

NM_020338.4:c.2330G>A (p.Gly777Glu) Pathogenic

Gene: ZMIZ1 hgnc:16493

De novo missense substitution in exon 20 affecting the SP-RING/MIZ zinc finger domain, predicted to disturb the domain's spatial conformation and hence partner binding and SUMO E3 ligase function.

Show evidence (2 references)

PMID:35432459 SUPPORT Human Clinical

"A de novo heterozygous missense variant (c.2330G > A, p.Gly777Glu, G777E) was identified in the exon 20 of ZMIZ1."

Names the allele, its de novo origin, and its exon location.

PMID:35432459 SUPPORT Computational

"It was predicted that G777E was pathogenic and detrimental to the spatial conformation of the MIZ/SP-RING zinc finger domain of ZMIZ1."

In silico structural prediction of the functional consequence. Classified COMPUTATIONAL because the claim rests on protein structure prediction, not a wet-lab assay.

NM_020338.4:c.858_875del (p.Val288_Ala293del) Pathogenic

Gene: ZMIZ1 hgnc:16493

In-frame six-codon deletion altering the alanine-rich domain; reduces mutant ZMIZ1 protein abundance in cell-based assays.

Show evidence (1 reference)

PMID:38117436 SUPPORT Human Clinical

"WES revealed a non-frameshift deletion variant in ZMIZ1 (NM_020338.4: c.858_875del, p.Val288_Ala293del), resulting in a structural alteration in the protein's alanine-rich domain."

Names the allele and localizes it to the alanine-rich domain.

NM_020338.4:c.2633dup (p.Gly879ArgfsTer22) Pathogenic

Gene: ZMIZ1 hgnc:16493

De novo frameshifting duplication in the C-terminal transactivation region, identified prenatally by whole-exome sequencing on amniotic fluid in a fetus with microcephaly, short femur, and intrauterine growth restriction.

Show evidence (1 reference)

PMID:41918386 SUPPORT Human Clinical

"WES revealed that the fetus harbored a de novo heterozygous frameshift variant c.2633dup (p.Gly879ArgfsTer22) of the ZMIZ1 gene, which was rated as pathogenic (PM2_Supporting+PS2_Supporting+PVS1)."

Names the allele, its de novo origin, and its ACMG pathogenic classification.

NM_020338.4:c.910G>C (p.Ala304Pro) Likely Pathogenic

Gene: ZMIZ1 hgnc:16493

De novo missense substitution in the alanine-rich region. Unusually among reported alleles it raises rather than lowers ZMIZ1 mRNA and protein levels and mislocalizes the protein, arguing against a uniform haploinsufficiency mechanism. The measurement was made on transfected constructs in human skeletal muscle cells and HEK293T cells, not endogenous patient cells, so it is better read as altered protein stability than as patient-level upregulation.

Show evidence (2 references)

PMID:41354990 SUPPORT Human Clinical

"Here, we identified a novel de novo missense variant c.910G>C (p.A304P) in ZMIZ1 in a patient with NEDDFSA."

Names the allele, its de novo origin, and the clinical diagnosis.

PMID:41354990 SUPPORT Other

"Our study identifies a novel likely pathogenic variant in ZMIZ1 associated with NEDDFSA."

Sources the likely-pathogenic classification recorded on this variant. Classified OTHER because this is a variant-classification statement rather than a report of experimental data.

💊

Medical Actions

2

Multidisciplinary Supportive and Developmental Care

Action: Supportive Care NCIT:C15747

No disease-modifying therapy exists. Management is entirely supportive and anticipatory, directed at the individual features: nutritional support for the infantile feeding difficulty and growth failure, early intervention with physical, occupational, and speech therapy for the hypotonia and developmental delay, ophthalmological assessment and management (ptosis repair, refractive correction, amblyopia therapy) given that ptosis and refractive error are the leading eye findings, audiological surveillance because sensorineural hearing loss affects roughly a third of individuals, orthopaedic assessment for hip dysplasia and distal limb anomalies, seizure management where relevant, and cardiac and renal imaging given the reported congenital heart and genitourinary anomalies.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Counseling should cover the autosomal dominant mechanism, the 50 percent recurrence risk for an affected parent, and the low but non-zero recurrence risk after an apparently de novo case (parental germline mosaicism cannot be excluded). Testing both parents is specifically indicated rather than optional, because a transmitting parent may be only mildly affected and would otherwise be missed — the family reported with c.1310delC included an affected father identified only after his sons were diagnosed. Prenatal diagnosis by exome sequencing on amniotic fluid has been performed successfully.

Show evidence (2 references)

PMID:31833199 SUPPORT Human Clinical

"parental testing to identify a mildly affected parent is needed"

Directly supports the recommendation that both parents be tested rather than assuming de novo occurrence.

PMID:41918386 SUPPORT Human Clinical

"Genetic testing has enabled accurate prenatal diagnosis and provided evidence for genetic counseling and reproductive guidance of this family."

Supports the availability and utility of prenatal diagnosis and genetic counseling in this disorder.

🔬

Diagnosis

1

Molecular Genetic Testing

Diagnosis rests on identification of a heterozygous pathogenic ZMIZ1 variant. In practice every reported diagnosis has come from exome sequencing or a broad multigene panel rather than from targeted single-gene testing, because the clinical gestalt is not specific enough to prompt a directed test. Chromosomal microarray and structural-variant analysis remain relevant because balanced translocations disrupting ZMIZ1 or its regulatory region also cause the disorder and are invisible to standard exome analysis. Trio testing is preferred: most variants are de novo, and where they are not, the transmitting parent may be only mildly affected and requires targeted testing to identify.

Show evidence (3 references)

PMID:41918386 SUPPORT Human Clinical

"Whole-exome sequencing (WES) was carried out on the amniotic fluid and parental peripheral blood samples, and candidate variants was verified by Sanger sequencing."

Illustrates the trio exome-plus-Sanger workflow, here applied prenatally.

PMID:30639322 SUPPORT Human Clinical

"2 subjects had a balanced translocation disrupting ZMIZ1 or involving a regulatory region of ZMIZ1"

Justifies retaining cytogenomic/structural testing alongside sequencing, since translocation and regulatory lesions also cause the disorder.

PMID:31833199 SUPPORT Human Clinical

"parental testing to identify a mildly affected parent is needed"

Supports the recommendation for parental testing rather than assuming de novo occurrence.

📊

Prevalence

1

Worldwide

Cases In Literature Ultra Rare

Fewer than forty individuals reported since the syndrome was delineated in 2019. A 2025 systematic re-analysis assembled 36 individuals with coding ZMIZ1 variants from 15 publications; a 2024 ophthalmology-focused review found 27 published cases. No population prevalence estimate exists and none should be inferred from these case counts.

Show evidence (2 references)

PMID:40529245 SUPPORT Human Clinical

"This study includes descriptions of ZMIZ1 disease-associated variants of 36 individuals diagnosed with NDDs: 35 single-nucleotide variants (SNVs) and 1 deletion, all in the coding sequence."

Gives the size of the assembled published case series, supporting the ultra-rare / cases-in-literature classification.

PMID:39658964 SUPPORT Human Clinical

"Review of the literature permitted the analysis of 27 cases of ZMIZ1 variants in patients with syndromic phenotypes."

Independent case count from a separate systematic literature review, corroborating the very small number of reported individuals.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Neurodevelopmental Disorder with Dysmorphic Facies and Distal Skeletal Anomalies:

Neurodevelopmental Disorder with Dysmorphic Facies and Distal Limb Anomalies (NEDDFL, BPTF) MONDO:0060596

Overlapping Features The single most important label hazard for this entry. NEDDFL (MONDO:0060596, OMIM:617755) is caused by heterozygous variants in BPTF (HGNC:3581), a bromodomain PHD finger chromatin-remodeling transcription factor. Its name differs from this disorder's by one word — "limb" versus "skeletal" — and both are autosomal dominant syndromic neurodevelopmental disorders with developmental delay, dysmorphic facies, microcephaly, and distal anomalies. They are separate entities with separate causal genes and must never be pooled.

Distinguishing Features

Molecular: BPTF (HGNC:3581), a bromodomain/PHD-finger chromatin remodeler, versus ZMIZ1 (hgnc:16493), a PIAS-family SUMO E3 ligase and transcriptional coactivator. Different genes, different chromosomes, different protein families. This is the definitive discriminator and requires sequencing.
Nomenclature: "distal LIMB anomalies" (NEDDFL, BPTF, OMIM:617755) versus "distal SKELETAL anomalies" (NEDDFSA, ZMIZ1, OMIM:618659). Curators and automated literature-mining tools must key on the gene or the OMIM number, never on the disease name alone.
Clinical emphasis: postnatal microcephaly and speech delay are prominent in NEDDFL, whereas the ZMIZ1 disorder is anchored on early hypotonia, poor feeding and growth failure, joint hypermobility, and ptosis as the leading ocular sign.

OTUD6B-Related Neurodevelopmental Disorder (IDDFSDA) MONDO:0044319

Overlapping Features An autosomal recessive syndromic intellectual disability caused by biallelic OTUD6B variants, sharing facial dysmorphism, distal limb anomalies, and seizures with this disorder. Crucially, the two are not merely confusable: PMID:34680978 reports a single 5-year-old girl who genuinely carries disease-relevant variants at BOTH loci — a hemizygous OTUD6B c.873delA over a paternally inherited 8q21.3 whole-gene deletion, together with a heterozygous ZMIZ1 c.1491+2T>C splice variant shown by mRNA study to skip exon 14. Finding a ZMIZ1 variant therefore does not exclude OTUD6B disease, and vice versa.

Distinguishing Features

Inheritance: OTUD6B disease is autosomal recessive (biallelic), this disorder is autosomal dominant (heterozygous). This alone usually separates them on a trio exome.
Molecular: OTUD6B is a deubiquitinase; ZMIZ1 is a transcriptional coactivator and SUMO E3 ligase. No shared mechanism, so evidence must not be pooled across the two entries.

Show evidence (2 references)

PMID:34680978 SUPPORT Human Clinical

"The OTUD6B and ZMIZ1 genes were recently identified as causes of syndromic intellectual disability (ID) with shared phenotypes of facial dysmorphism, distal limb anomalies, and seizure disorders."

States the phenotypic overlap that makes OTUD6B disease a differential, in the authors' own words.

PMID:34680978 SUPPORT Human Clinical

"OTUD6B- and ZMIZ1-related ID are inherited in autosomal recessive and autosomal dominant patterns, respectively."

Sources the inheritance-mode discriminator between the two entities.

📊

Related Datasets

1

RNA sequencing on Postnatal day (P) 7 wildtype and Zmiz1-Knockout cortex GEO:GSE225435

Cortical RNA-seq from the Emx1-Cre forebrain-specific Zmiz1 knockout, the primary transcriptomic dataset behind the "Dysregulated Developmental Transcriptional Programs" node. It identified 114 differentially expressed genes at postnatal day 7, with downregulated genes enriched for forebrain development, axon development, and neuron differentiation.

mouse BULK RNA SEQ

PMID:41633496

Mouse cortex, not human tissue. No patient-derived transcriptomic dataset exists for this disorder, which is the calibration caveat recorded on the developmental-transcriptional-programs node.

Show evidence (1 reference)

GEO:GSE225435 SUPPORT Model Organism

"We found 114 differentially expressed genes of which 35 genes were upregulated while 69 genes were downregulated. Downregulated genes were enriched in biological processes such as forebrain deveopment, axon development, neuron differentiation etc."

Quantifies the transcriptional dysregulation asserted by the developmental-transcriptional-programs node, and names the enriched processes. The typo "deveopment" is present in the source record and is reproduced verbatim so the snippet validates.

🐁

Animal Models

2

Forebrain-specific conditional Zmiz1 knockout Mus musculus Conditional loss-of-function mouse model of ZMIZ1 syndrome

The principal in vivo loss-of-function model of this disorder, reported in PMID:41633496. It reproduces cortical microcephaly, corpus callosum dysgenesis, and abnormal differentiation of upper-layer cortical neurons, together with autism-like behavioral changes in motor activity, anxiety, communication, and social interaction with strong sex differences. RNA-seq plus ChIP-seq identified Lhx2, Auts2, and EfnB2 as ZMIZ1-regulated neurodevelopmental targets, and reactivation of the ephrin-B2 pathway rescued the dendritic outgrowth deficit — the first mechanistic rescue reported for this disorder. It models the "Impaired Cortical Neurogenesis, Neuronal Differentiation, and Positioning" and "Dysregulated Developmental Transcriptional Programs" pathophysiology nodes. Face validity for the neurological arm is good, but because Zmiz1 deletion is restricted to forebrain the model cannot address the craniofacial, distal skeletal, cardiac, or genitourinary features, which therefore remain unmodeled.

Species

Mus musculus

Genotype

Forebrain-specific conditional Zmiz1 knockout

Show evidence (2 references)

PMID:41633496 SUPPORT Model Organism

"We generated forebrain-specific Zmiz1 mutant mice (Zmiz1-knockout) to assess ZMIZ1 function in cortical development."

Describes the model construction.

PMID:41633496 SUPPORT Model Organism

"Loss of ZMIZ1 led to cortical microcephaly, corpus callosum dysgenesis, and abnormal differentiation of upper-layer cortical neurons."

Establishes the structural brain phenotypes recapitulated by the model.

In utero electroporation of patient ZMIZ1 mutant alleles into embryonic cortex Mus musculus Acute somatic overexpression model of patient alleles

An acute somatic model, reported in PMID:30639322, in which patient-derived ZMIZ1 mutant alleles were introduced into cortical progenitors of the embryonic mouse ventricular zone by in utero electroporation. Mutant alleles produced abnormal pyramidal neuron morphology, polarization, and positioning. This was the in vivo evidence that established the pathogenicity of the human alleles and models the "Impaired Cortical Neurogenesis, Neuronal Differentiation, and Positioning" node. Interpretive caveat: it is an overexpression paradigm, not an endogenous knock-in, so it cannot distinguish loss of function from dominant-negative or gain-of-function effects; the conditional knockout above is the complementary loss-of-function test.

Species

Mus musculus

Genotype

In utero electroporation of patient ZMIZ1 mutant alleles into embryonic cortex

Show evidence (1 reference)

PMID:30639322 SUPPORT Model Organism

"In vivo, overexpression of ZMIZ1 mutant alleles in developing mouse brains using in utero electroporation resulted in abnormal pyramidal neuron morphology, polarization, and positioning"

Describes the model and its principal readout, linking human alleles to a cortical developmental defect.

{ }

Source YAML

click to show

name: Neurodevelopmental Disorder with Dysmorphic Facies and Distal Skeletal Anomalies
creation_date: "2026-08-15T00:00:00Z"
description: >-
  Neurodevelopmental disorder with dysmorphic facies and distal skeletal
  anomalies (NEDDFSA, OMIM 618659) is a rare autosomal dominant syndromic
  neurodevelopmental disorder caused by heterozygous variants in ZMIZ1, which
  encodes a PIAS-family zinc finger MIZ-type transcriptional coactivator and
  SUMO E3 ligase. Affected individuals typically present in early infancy with
  poor feeding, poor overall growth, and hypotonia, followed by mildly delayed
  motor development, poor language acquisition, and behavioral abnormalities.
  Intellectual outcome is strikingly variable, ranging from severe impairment
  to normal cognition even within a single family. The syndrome is completed by
  a recognizable pattern of facial dysmorphism, distal skeletal anomalies of
  the hands and feet, joint hypermobility, and ocular findings — ptosis is the
  single most common eye feature. Microcephaly is common (64% of imaged
  individuals) and sensorineural hearing loss affects about a third, while
  seizures, congenital heart defects, and genitourinary anomalies occur in a
  minority. ZMIZ1 acts as a coactivator for NOTCH1, the androgen receptor, p53,
  and SMAD3/4, and interacts with the BAF chromatin remodeling complex, so the
  disorder is best understood as a transcriptional-coregulator disease in which
  developmental transcriptional programs — cortical neurogenesis, neuronal
  differentiation and positioning, dendritic outgrowth, and skeletal
  patterning — are dysregulated. The entity was delineated only in 2019 and
  fewer than forty individuals have been reported, so phenotype frequencies
  should be read as provisional.
category: Mendelian
parents:
- hereditary disease
- Neurodevelopmental Disorder
synonyms:
- NEDDFSA
- ZMIZ1-related neurodevelopmental disorder
- ZMIZ1 syndrome
- ZMIZ1-related syndromic intellectual disability
disease_term:
  preferred_term: ZMIZ1-related neurodevelopmental disorder (NEDDFSA)
  term:
    id: MONDO:0032855
    label: neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies
notes: >-
  Identifiers. MONDO:0032855; OMIM:618659; MedGen C5231448; GARD 0018521;
  UMLS C5231448; causal gene ZMIZ1 (hgnc:16493, 10q22.3). Orphanet has no
  dedicated ORPHA code for this entity as of curation.

  Named-entity-confusion preflight. This entity sits in a large family of
  near-identically named OMIM "neurodevelopmental disorder with ..." entries and
  was treated as high NEC risk during curation. The MONDO record for
  MONDO:0032855 was pulled with OAK on 2026-08-15 and gives three concordant
  identity anchors: "relationship: RO:0004003 HGNC:16493 ! ZMIZ1",
  "xref: OMIM:618659", and the RELATED synonym "NEDDFSA". Every clinical paper
  cited in this entry names ZMIZ1 as the causal gene, so gene, OMIM ID, and
  synonym all agree and no NEC discard was triggered. The Edison/falcon
  deep-research report used for this entry also passed the automated
  gene-frequency preflight (just preflight-dr): ZMIZ1 was mentioned 41 times
  against a next-highest gene count of 3 (AR), and the report's OMIM number
  matched the MONDO xref.

  The single most dangerous confusable is "neurodevelopmental disorder with
  dysmorphic facies and distal LIMB anomalies" (NEDDFL, MONDO:0060596,
  OMIM:617755), caused by BPTF (HGNC:3581). The labels differ by one word,
  "skeletal" versus "limb". NEDDFL is recorded here under
  differential_diagnoses. Note that as of this entry's creation there is NO
  NEDDFL/BPTF entry in kb/disorders — MONDO:0060596 appears in the KB only as a
  differential reference from this entry and from the OTUD6B entry — so a future
  curator must not assume the confusable is already covered elsewhere. Nothing
  in this entry may be sourced from BPTF literature.

  Dual-genotype confound in PMID:34680978. That report describes a 5-year-old
  Thai girl who carries BOTH a hemizygous OTUD6B c.873delA over a paternally
  inherited 8q21.3 whole-gene deletion AND a heterozygous ZMIZ1 c.1491 + 2T > C
  splice variant shown by mRNA study to skip exon 14. Her clinical features
  (Williams syndrome-like facial gestalt with periorbital edema, hanging cheek,
  long and smooth philtrum; cardiac defects; terminal broadening of the fingers;
  polydactyly) cannot be attributed cleanly to either locus, and the authors
  themselves assign the Williams-like features to the OTUD6B side. This entry
  therefore does NOT curate any phenotype from that proband. PMID:34680978
  appears exactly FIVE times in this file, and every one is accounted for here:
  (1) genetic[0].evidence[4], the mRNA-study observation that the splice variant
  skips exon 14, supports: PARTIAL; (2) genetic[0].evidence[5], the observation
  that the allele was inherited from the father, supports: PARTIAL;
  (3) differential_diagnoses[1].evidence[0], the authors' statement of the
  phenotypic overlap between ZMIZ1 and OTUD6B disease, supports: SUPPORT;
  (4) differential_diagnoses[1].evidence[1], the inheritance-mode discriminator
  between the two entities, supports: SUPPORT; and (5) one bibliography entry in
  the top-level references list, which carries no snippet and asserts nothing.
  All four evidence citations restate the dual-genotype confound in their
  explanation, and none of them attributes a phenotype to ZMIZ1. The reciprocal
  caveat is already recorded in the dismech OTUD6B-Related Neurodevelopmental
  Disorder entry.

  No GeneReviews chapter exists. PubMed searches for "ZMIZ1 GeneReviews" and
  "neurodevelopmental disorder with dysmorphic facies and distal skeletal
  anomalies GeneReviews" both returned zero results on 2026-08-15, so no
  GeneReviews phenotype baseline was available and the phenotype set is built
  from the primary case literature and the two published cohort/meta-analyses
  (PMID:39658964, PMID:40529245).

  Beyond-abstract sourcing. Several cached references (PMID:35432459,
  PMID:38686122, PMID:41354990, PMID:41633496) are cached as full text rather
  than abstract-only, and linkml-reference-validator checks snippets against the
  cached body. Evidence items in this entry therefore quote figures and
  Results-section sentences from those papers as well as abstract text; each such
  snippet was confirmed against the cached file before use. Where a paper is
  cached abstract-only, quotes are confined to the abstract.

  ZMIZ1-PRR12 translocation. A balanced t(10;19)(q22.3;q13.33) disrupting ZMIZ1
  and PRR12 was reported before the syndrome was delineated. PRR12 causes its
  own distinct disorder (PRR12-related neuroocular syndrome, curated separately
  in dismech), so translocation cases that disrupt both genes are not clean
  ZMIZ1 evidence and are not used for phenotype curation here.
inheritance:
- name: Autosomal dominant inheritance
  description: >-
    Disease results from a single heterozygous ZMIZ1 allele. The great majority
    of reported variants arose de novo, but vertical transmission is
    established: a father and his two sons all carry the same pathogenic
    frameshift allele c.1310delC (p.Pro437ArgfsX84). Expressivity within that
    family was markedly variable — severity of intellectual disability and
    eyelid ptosis differed between affected members and only one of the two
    children had sensorineural hearing loss — so a mildly affected transmitting
    parent can easily be missed without targeted parental testing.
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  expressivity: VARIABLE
  evidence:
  - reference: PMID:35432459
    reference_title: "A de Novo ZMIZ1 Pathogenic Variant for Neurodevelopmental Disorder With Dysmorphic Facies and Distal Skeletal Anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NEDDFSA is caused by heterozygous pathogenic variants in the ZMIZ1 gene on
      chromosome 10q22.3 with autosomal dominant (AD) mode of inheritance.
    explanation: >-
      States the mode of inheritance and the heterozygous, single-allele
      mechanism for the named entity NEDDFSA.
  - reference: PMID:31833199
    reference_title: "Autosomal dominant inheritance in a recently described ZMIZ1-related neurodevelopmental disorder: Case report of siblings and an affected parent."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we report on a father and his two sons demonstrating autosomal dominant
      inheritance of a novel pathogenic ZMIZ1 variant, c.1310delC
      (p.Pro437ArgfsX84), causing this recently described neurodevelopmental
      syndrome.
    explanation: >-
      Documents germline transmission across two generations, confirming
      dominant inheritance rather than exclusively de novo occurrence.
  - reference: PMID:31833199
    reference_title: "Autosomal dominant inheritance in a recently described ZMIZ1-related neurodevelopmental disorder: Case report of siblings and an affected parent."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our report demonstrates that phenotypic features of ZMIZ1-related
      neurodevelopmental syndrome are variable even within the same family and
      that parental testing to identify a mildly affected parent is needed.
    explanation: >-
      Supports the variable-expressivity classification and the clinical
      implication that transmitting parents may be only mildly affected.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Fewer than forty individuals reported since the syndrome was delineated in
    2019. A 2025 systematic re-analysis assembled 36 individuals with coding
    ZMIZ1 variants from 15 publications; a 2024 ophthalmology-focused review
    found 27 published cases. No population prevalence estimate exists and none
    should be inferred from these case counts.
  evidence:
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study includes descriptions of ZMIZ1 disease-associated variants of
      36 individuals diagnosed with NDDs: 35 single-nucleotide variants (SNVs)
      and 1 deletion, all in the coding sequence.
    explanation: >-
      Gives the size of the assembled published case series, supporting the
      ultra-rare / cases-in-literature classification.
  - reference: PMID:39658964
    reference_title: "A novel ZMIZ1 variant associated with NEDDFSA and new ocular features: case report and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Review of the literature permitted the analysis of 27 cases of ZMIZ1
      variants in patients with syndromic phenotypes.
    explanation: >-
      Independent case count from a separate systematic literature review,
      corroborating the very small number of reported individuals.
pathophysiology:
- name: Heterozygous ZMIZ1 Variant
  description: >-
    A single heterozygous variant in ZMIZ1 (10q22.3) is the initiating lesion.
    Reported alleles are overwhelmingly de novo and are distributed across the
    coding sequence but cluster in functionally defined regions: the N-terminal
    tetratricopeptide repeat (TPR) that mediates NOTCH1 binding, the central
    intrinsically disordered alanine-rich motif, the proline-rich domains, the
    SP-RING/MIZ zinc finger, and the C-terminal transactivation domain. Both
    missense substitutions and frameshifting truncations occur, and structural
    lesions (balanced translocations disrupting ZMIZ1 or its regulatory region)
    have also been reported. ZMIZ1 is strongly constrained against
    loss-of-function variation in population data, consistent with dosage
    sensitivity. Functional consequences documented so far are nonetheless
    heterogeneous: an alanine-rich in-frame deletion reduced mutant protein
    abundance, whereas a different alanine-rich missense allele increased ZMIZ1
    expression and mislocalized the protein, so a simple haploinsufficiency
    model does not account for every allele. The latter measurement comes from
    transfected constructs in skeletal muscle and HEK293T cells rather than
    endogenous patient cells, so it more plausibly reports altered protein
    stability than patient-level upregulation.
  biological_scale: MOLECULAR
  gene:
    preferred_term: ZMIZ1
    term:
      id: hgnc:16493
      label: ZMIZ1
  mechanism_confidence: ESTABLISHED
  downstream:
  - target: Impaired PIAS-Family Coactivator Function
    causal_link_type: DIRECT
    description: >-
      Variants in the domains that mediate partner binding, SUMO E3 ligase
      activity, and transactivation directly degrade ZMIZ1 coregulator function.
  evidence:
  - reference: PMID:30639322
    reference_title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of these 19, 14 unrelated subjects carried de novo heterozygous
      single-nucleotide variants (SNVs) or single-base insertions/deletions, 3
      siblings harbored a heterozygous single-base insertion, and 2 subjects had
      a balanced translocation disrupting ZMIZ1 or involving a regulatory region
      of ZMIZ1.
    explanation: >-
      Establishes the heterozygous, largely de novo allelic architecture and the
      existence of structural as well as point lesions.
  - reference: PMID:30639322
    reference_title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In total, we identified 13 point mutations that affect key protein
      regions, including a SUMO acceptor site, a central disordered alanine-rich
      motif, a proline-rich domain, and a transactivation domain.
    explanation: >-
      Localizes the pathogenic point mutations to the functional regions that
      carry ZMIZ1 coregulator activity.
  - reference: PMID:38686122
    reference_title: "Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      Zmiz1 has an oe-score of 0.13 for loss-of-function mutations (observed
      SNVs 7/expected SNVs 52.1), which indicates that only 13% of the expected
      loss-of-function variants were observed in sampled data.
    explanation: >-
      Population-genetic constraint metric supporting dosage sensitivity of
      ZMIZ1. Classified COMPUTATIONAL because it is derived from a
      variant-database observed/expected calculation, not a wet-lab assay.
  - reference: PMID:38117436
    reference_title: "Clinical report and genetic analysis of a novel variant in ZMIZ1 causing neurodevelopmental disorder with dysmorphic factors and distal skeletal anomalies in a Chinese family."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Western blot and immunofluorescence assays indicated a significant
      decrease in the expression level of the mutant ZMIZ1 protein compared to
      the wild-type protein.
    explanation: >-
      Direct cell-based demonstration that an alanine-rich-domain in-frame
      deletion allele reduces ZMIZ1 protein abundance, one documented route from
      variant to loss of coregulator dosage.
  - reference: PMID:41354990
    reference_title: "Genetic and functional analysis of ZMIZ1 in neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NEDDFSA): insights from muscle cells and signaling pathways."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The p.A304P variant significantly increased ZMIZ1 mRNA and protein
      expression levels and altered its subcellular localization.
    explanation: >-
      Supports the statement that allelic consequences are heterogeneous — this
      variant raises rather than lowers ZMIZ1 levels — so the mechanism is not
      uniformly simple haploinsufficiency. Marked PARTIAL because it is a single
      allele assayed in skeletal muscle cells, not neurons.
- name: Impaired PIAS-Family Coactivator Function
  description: >-
    ZMIZ1 is a PIAS-family transcriptional coregulator built around a conserved
    MIZ (Msx-interacting zinc finger) SP-RING domain that confers SUMO E3 ligase
    activity, an N-terminal TPR that binds NOTCH1, and a C-terminal
    transactivation domain. It does not bind DNA on its own; it potentiates
    signal-dependent transcription factors — NOTCH1, the androgen receptor, p53,
    and SMAD3/4 — and works with the BAF (SWI/SNF) chromatin remodeling complex.
    Pathogenic variants degrade this coactivation function. The
    best-characterized readout is androgen receptor coactivation, which is
    measurably impaired in vitro by patient alleles; a newly described
    interaction with the general transcription factor GTF2I and dysregulation of
    TGF-beta1 pathway genes suggest the coregulator hub is broader than the four
    classical partners.
  biological_scale: MOLECULAR
  molecular_functions:
  - preferred_term: transcription coactivator activity
    term:
      id: GO:0003713
      label: transcription coactivator activity
    modifier: DECREASED
  - preferred_term: SUMO E3 ligase activity
    term:
      id: GO:0019789
      label: SUMO transferase activity
  biological_processes:
  - preferred_term: Notch signaling pathway
    term:
      id: GO:0007219
      label: Notch signaling pathway
    modifier: ABNORMAL
  - preferred_term: androgen receptor signaling pathway
    term:
      id: GO:0030521
      label: androgen receptor signaling pathway
    modifier: DECREASED
  - preferred_term: protein sumoylation
    term:
      id: GO:0016925
      label: protein sumoylation
  - preferred_term: chromatin remodeling
    term:
      id: GO:0006338
      label: chromatin remodeling
    modifier: ABNORMAL
  mechanism_confidence: ESTABLISHED
  downstream:
  - target: Dysregulated Developmental Transcriptional Programs
    causal_link_type: DIRECT
    description: >-
      Loss of coactivator potency at NOTCH1, AR, p53, and SMAD3/4 target
      promoters changes the output of the transcriptional programs those
      pathways drive.
  evidence:
  - reference: PMID:30639322
    reference_title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      ZMIZ1 is a coactivator of several transcription factors, including p53,
      the androgen receptor, and NOTCH1.
    explanation: >-
      Establishes the coactivator identity and names the three classical
      transcription-factor partners on which the mechanism turns.
  - reference: PMID:30639322
    reference_title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In vitro, ZMIZ1 showed impaired coactivation of the androgen receptor."
    explanation: >-
      Direct functional demonstration that patient variants degrade ZMIZ1
      coactivation, the central molecular claim of this node.
  - reference: PMID:35670836
    reference_title: "ZMIZ proteins: partners in transcriptional regulation and risk factors for human disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Among other interacting domains, they possess a MIZ (Msx-interacting zinc
      finger) that relates them to members of the protein inhibitor of activated
      STAT (PIAS) family and provides them the capacity to function as SUMO E3
      ligases.
    explanation: >-
      Sources the PIAS-family assignment and the SUMO E3 ligase activity carried
      by the MIZ/SP-RING domain. Classified OTHER because the source is a
      narrative expert review rather than primary data.
  - reference: PMID:35670836
    reference_title: "ZMIZ proteins: partners in transcriptional regulation and risk factors for human disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The ZMIZ proteins stimulate the activity of various signaling pathways,
      including the androgen receptor (AR), P53, SMAD3/4, WNT/β-catenin, and
      NOTCH1 pathways, and interact with the BAF chromatin remodeling complex.
    explanation: >-
      Sources the full partner set including SMAD3/4 and the BAF chromatin
      remodeling interaction cited in the node description.
  - reference: PMID:41354990
    reference_title: "Genetic and functional analysis of ZMIZ1 in neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NEDDFSA): insights from muscle cells and signaling pathways."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Additionally, we identified a novel interaction between ZMIZ1 and the
      transcription factor GTF2I.
    explanation: >-
      Supports the statement that the ZMIZ1 coregulator hub extends beyond the
      four classical partners.
  - reference: PMID:41354990
    reference_title: "Genetic and functional analysis of ZMIZ1 in neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NEDDFSA): insights from muscle cells and signaling pathways."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      qPCR validation revealed significant dysregulation of key genes in the
      TGF-β1 signaling pathway.
    explanation: >-
      Links a NEDDFSA patient allele to altered TGF-beta/SMAD-axis
      transcriptional output, consistent with the SMAD3/4 partnership.
- name: Dysregulated Developmental Transcriptional Programs
  description: >-
    ZMIZ1 is most highly expressed during embryonic brain development in both
    mouse and human and is enriched in cortex, hippocampus, and cerebellum — the
    regions most implicated in intellectual disability and autism. Loss of
    ZMIZ1 function changes the transcriptional programs governing neurogenesis,
    neuronal differentiation, and synaptic signaling. In a forebrain-specific
    Zmiz1 knockout mouse, ZMIZ1 was shown by RNA-seq and ChIP-seq to regulate
    key neurodevelopmental effectors including Lhx2, Auts2, and EfnB2, and the
    ZMIZ1 interaction network is enriched for autism-associated genes. Because
    the same coactivator serves NOTCH1, AR, p53, and SMAD3/4 in non-neural
    tissue, the same lesion perturbs craniofacial, skeletal, cardiac, and
    genitourinary developmental programs, which is why the disorder is syndromic
    rather than purely neurological.
  biological_scale: MOLECULAR
  biological_processes:
  - preferred_term: regulation of transcription by RNA polymerase II
    term:
      id: GO:0006357
      label: regulation of transcription by RNA polymerase II
    modifier: ABNORMAL
  - preferred_term: neurogenesis
    term:
      id: GO:0022008
      label: neurogenesis
    modifier: ABNORMAL
  - preferred_term: skeletal system development
    term:
      id: GO:0001501
      label: skeletal system development
    modifier: ABNORMAL
  - preferred_term: ephrin receptor signaling pathway
    term:
      id: GO:0048013
      label: ephrin receptor signaling pathway
    modifier: DECREASED
  mechanism_confidence: ESTABLISHED
  notes: >-
    Confidence calibration: the coactivator-to-transcriptional-output link is
    established biology and is reinforced in humans by the severe
    loss-of-function constraint on ZMIZ1, but every direct readout of the
    dysregulated programs cited here is model-organism data (mouse RNA-seq and
    ChIP-seq). No patient-derived transcriptomic or methylation signature has
    been published, so the human specificity of the affected programs is
    inferred rather than measured.
  downstream:
  - target: Impaired Cortical Neurogenesis, Neuronal Differentiation, and Positioning
    causal_link_type: DIRECT
    description: >-
      The neural arm of the transcriptional dysregulation, expressed in cortical
      progenitors and their projection-neuron progeny.
  - target: Disrupted Craniofacial and Distal Skeletal Patterning
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The non-neural arm. ZMIZ1 is broadly expressed in embryonic tissues and
      partners with SMAD3/4 and NOTCH1, both central to skeletal and
      craniofacial morphogenesis, but the specific target genes that produce
      the human facial and distal limb phenotype have not been identified.
  evidence:
  - reference: PMID:38686122
    reference_title: "Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Zmiz1 is highly expressed during embryonic brain development in mice and
      humans, and though broadly expressed across the brain, Zmiz1 is enriched
      in areas prominently impacted in ID and ASD such as cortex, hippocampus,
      and cerebellum.
    explanation: >-
      Establishes the developmental timing and regional enrichment that make
      ZMIZ1 loss a developmental-transcription problem. Classified OTHER because
      the statement is derived from mining public expression atlases spanning
      both mouse and human, not from an experiment performed in an animal model.
  - reference: PMID:38686122
    reference_title: "Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Our analysis reveals that Zmiz1 regulates multiple developmental
      processes, including neurogenesis, neuron connectivity, and synaptic
      signaling.
    explanation: >-
      Names the specific developmental programs under ZMIZ1 transcriptional
      control.
  - reference: PMID:41633496
    reference_title: "Loss of Zmiz1 in Mice Leads to Impaired Cortical Development and Autistic-Like Behaviors."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We identified Zmiz1-mediated downstream regulation of key
      neurodevelopmental genes, including Lhx2, Auts2, and EfnB2.
    explanation: >-
      Identifies the specific transcriptional targets through which ZMIZ1 loss
      is transmitted to cortical development.
  - reference: PMID:41633496
    reference_title: "Loss of Zmiz1 in Mice Leads to Impaired Cortical Development and Autistic-Like Behaviors."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Zmiz1 mutation led to transcriptomic changes disrupting neurogenesis,
      neuron differentiation programs, and synaptic signaling.
    explanation: >-
      Direct transcriptomic evidence that ZMIZ1 loss dysregulates the named
      developmental programs.
- name: Impaired Cortical Neurogenesis, Neuronal Differentiation, and Positioning
  description: >-
    The cellular consequence in the developing cortex, comprising reduced
    progenitor output, impaired neuronal differentiation and dendritic
    outgrowth, and abnormal neuronal positioning. The two mouse paradigms
    disagree on the positioning component and that disagreement is curated
    explicitly rather than smoothed over. In utero electroporation of patient
    ZMIZ1 mutant alleles into cortical progenitors produced abnormal pyramidal
    neuron morphology, polarization, and positioning, with mispositioned neurons
    accumulating in the ventricular, subventricular, and intermediate zones and
    depleted from the upper cortical plate. The complementary forebrain-specific
    Zmiz1 knockout reproduced cortical microcephaly, corpus callosum dysgenesis,
    and abnormal differentiation of upper-layer neurons, but its BrdU
    birthdating showed the surviving neurons were correctly positioned, so in
    that model microcephaly arises from reduced progenitor proliferation and
    neurogenesis rather than from a migration defect. The likeliest reconciliation
    is that the positioning phenotype is specific to the overexpression paradigm
    (see the neddfsa_allele_mechanism_direction discussion); note, however, that
    the human data independently support a positioning abnormality — cortical
    heterotopias were found at autopsy in one adult and on MRI in a majority of
    imaged patients. The dendritic outgrowth deficit in the knockout is rescued
    by reactivating the ephrin-B2 pathway, identifying a specific and in
    principle tractable effector arm; transcriptomically the same model
    disrupts synaptic-signaling gene programs.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: cortical pyramidal (projection) neuron
    term:
      id: CL:0000598
      label: pyramidal neuron
  - preferred_term: cortical neural progenitor cell
    term:
      id: CL:0011020
      label: neural progenitor cell
  biological_processes:
  - preferred_term: regulation of neurogenesis
    term:
      id: GO:0050767
      label: regulation of neurogenesis
    modifier: DECREASED
  - preferred_term: neuron migration
    term:
      id: GO:0001764
      label: neuron migration
    modifier: ABNORMAL
  - preferred_term: neuron differentiation
    term:
      id: GO:0030182
      label: neuron differentiation
    modifier: ABNORMAL
  - preferred_term: dendrite development
    term:
      id: GO:0016358
      label: dendrite development
    modifier: DECREASED
  - preferred_term: cerebral cortex development
    term:
      id: GO:0021987
      label: cerebral cortex development
    modifier: ABNORMAL
  - preferred_term: corpus callosum development
    term:
      id: GO:0022038
      label: corpus callosum development
    modifier: ABNORMAL
  - preferred_term: synaptic signaling
    term:
      id: GO:0099536
      label: synaptic signaling
    modifier: ABNORMAL
  mechanism_confidence: ESTABLISHED
  notes: >-
    The neuron migration annotation on this node is deliberately retained but is
    contested in mouse. It is supported by the in utero electroporation
    overexpression paradigm and by the human cortical heterotopias, and is
    explicitly refuted by BrdU birthdating in the forebrain-specific knockout,
    where migration was intact and microcephaly was attributable to reduced
    progenitor output. Both directions are curated as evidence items on this
    node.
  downstream:
  - target: Global Neurodevelopmental Impairment
    causal_link_type: DIRECT
    description: >-
      Miswired and mispositioned cortical circuitry is the substrate of the
      cognitive, language, motor, and behavioral phenotype.
  evidence:
  - reference: PMID:30639322
    reference_title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In vivo, overexpression of ZMIZ1 mutant alleles in developing mouse brains
      using in utero electroporation resulted in abnormal pyramidal neuron
      morphology, polarization, and positioning, underscoring the importance of
      ZMIZ1 in neural development
    explanation: >-
      Directly links patient alleles to abnormal pyramidal neuron morphology and
      positioning in vivo.
  - reference: PMID:35432459
    reference_title: "A de Novo ZMIZ1 Pathogenic Variant for Neurodevelopmental Disorder With Dysmorphic Facies and Distal Skeletal Anomalies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      resulted in impaired neuronal positioning with an accumulation in the
      ventricular and subventricular zones (VZ/SVZ) and intermediate zone (IZ)
      and a corresponding depletion in the upper cortical plate (CP)
    explanation: >-
      Specifies the laminar distribution of the positioning defect in the
      overexpression paradigm — retention in the proliferative and intermediate
      zones with depletion of the upper cortical plate. This is a secondary
      description of the PMID:30639322 experiment, quoted from the cached full
      text of PMID:35432459.
  - reference: PMID:41633496
    reference_title: "Loss of Zmiz1 in Mice Leads to Impaired Cortical Development and Autistic-Like Behaviors."
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Despite reduced numbers, BrdU+ neurons were correctly positioned according
      to their birthdates, indicating that migration was not disrupted
    explanation: >-
      Directly refutes the migration/positioning component of this node in the
      endogenous loss-of-function model: BrdU birthdating showed correct laminar
      positioning, so the microcephaly in that model reflects reduced progenitor
      proliferation and neurogenesis, not mispositioning. Curated as REFUTE so
      the contradiction with the overexpression paradigm is visible rather than
      averaged away.
  - reference: PMID:41633496
    reference_title: "Loss of Zmiz1 in Mice Leads to Impaired Cortical Development and Autistic-Like Behaviors."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Loss of ZMIZ1 led to cortical microcephaly, corpus callosum dysgenesis,
      and abnormal differentiation of upper-layer cortical neurons.
    explanation: >-
      Independent loss-of-function genetic model reproducing microcephaly,
      callosal dysgenesis, and upper-layer differentiation failure.
  - reference: PMID:41633496
    reference_title: "Loss of Zmiz1 in Mice Leads to Impaired Cortical Development and Autistic-Like Behaviors."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Importantly, reactivation of the ephrin-B2 pathway rescued the dendritic
      outgrowth deficits in Zmiz1 mutant cortical neurons.
    explanation: >-
      Establishes ephrin-B2 signaling as a downstream effector whose restoration
      rescues the dendritic phenotype — the rescue arm cited in this node.
  - reference: PMID:41039966
    reference_title: "ZMIZ1-Associated Neurodevelopmental Disorder in a 52-Year-Old Woman."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional findings seen on autopsy included cerebral cortical neuronal
      heterotopias.
    explanation: >-
      Human neuropathological counterpart of the neuronal migration and
      positioning defect demonstrated in the mouse models.
- name: Disrupted Craniofacial and Distal Skeletal Patterning
  description: >-
    The non-neural developmental arm that gives the syndrome its name. ZMIZ1 is
    expressed broadly in embryonic tissues beyond brain — including limb-forming
    mesoderm, heart, and kidney — and coactivates NOTCH1 and SMAD3/4, both
    central to craniofacial and appendicular skeletal morphogenesis. The
    clinical result is a recognizable dysmorphic facial pattern together with
    distal skeletal anomalies of the hands and feet, joint hypermobility, and
    hip dysplasia; prenatally the same program failure can present as short
    femur with intrauterine growth restriction. The specific ZMIZ1 target genes
    responsible have not been identified, and no skeletal-tissue model of the
    disorder exists, so this node is provisional relative to the well-worked
    cortical arm. The one direct functional study in a non-neural cell type
    (human skeletal muscle cells) showed a patient allele altering proliferation
    and migration and dysregulating TGF-beta1 pathway genes, which is
    suggestive but is muscle rather than cartilage or bone.
  biological_scale: TISSUE
  biological_processes:
  - preferred_term: skeletal system development
    term:
      id: GO:0001501
      label: skeletal system development
    modifier: ABNORMAL
  - preferred_term: transforming growth factor beta receptor signaling pathway
    term:
      id: GO:0007179
      label: transforming growth factor beta receptor signaling pathway
    modifier: ABNORMAL
  cell_types:
  - preferred_term: skeletal muscle cell
    term:
      id: CL:0000188
      label: cell of skeletal muscle
  mechanism_confidence: PROVISIONAL
  notes: >-
    Marked PROVISIONAL deliberately. The link from ZMIZ1 coactivator loss to the
    craniofacial and distal skeletal phenotype is inferred from the clinical
    pattern plus the known NOTCH1/SMAD partnership; unlike the cortical arm it
    has no dedicated in vivo skeletal model and no identified target genes. See
    the neddfsa_skeletal_arm_unmodeled discussion. The node also deliberately
    keeps the craniofacial (cranial-neural-crest) and appendicular
    (limb-mesenchyme) programs together, because no evidence yet distinguishes
    them in this disorder; splitting them should follow, not precede, the
    lineage-specific experiments proposed in that discussion.
  downstream:
  - target: Syndromic Multisystem Malformation
    causal_link_type: DIRECT
    description: >-
      Disrupted craniofacial and appendicular patterning is expressed at the
      level of the whole organism as the recognizable dysmorphic and skeletal
      syndrome, alongside the cardiac and genitourinary malformations that share
      the same coactivator-dependent developmental programs.
  evidence:
  - reference: PMID:35432459
    reference_title: "A de Novo ZMIZ1 Pathogenic Variant for Neurodevelopmental Disorder With Dysmorphic Facies and Distal Skeletal Anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neurodevelopmental disorder with dysmorphic facies and distal skeletal
      anomalies (NEDDFSA) is a rare syndromic disorder characterized by global
      neurodevelopmental delay, early-onset hypotonia, poor overall growth, poor
      speech/language ability, and additional common phenotypes such as eye
      anomalies, joint hypermobility, and skeletal anomalies of the hands and
      feet.
    explanation: >-
      Establishes that distal skeletal anomalies of the hands and feet and joint
      hypermobility are core, defining features requiring a non-neural
      developmental arm.
  - reference: PMID:41918386
    reference_title: "[A fetus with Neurodevelopmental disorders with deformed facial features and distal skeletal abnormalities due to a rare variant of ZMIZ1 gene and literature review]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Combined with 25 cases from the literature, the main manifestations of
      patients have included intellectual disability, growth retardation and
      cranio-limb skeletal dysplasia, albeit without clear genotype-phenotype
      correlation.
    explanation: >-
      Confirms cranio-limb skeletal dysplasia as a recurrent manifestation
      across the published series, and notes the absence of a
      genotype-phenotype correlation.
  - reference: PMID:41354990
    reference_title: "Genetic and functional analysis of ZMIZ1 in neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NEDDFSA): insights from muscle cells and signaling pathways."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Functional assays demonstrated enhanced proliferation and migration in
      HSkMCs expressing the mutant ZMIZ1.
    explanation: >-
      The only functional evidence for a ZMIZ1 patient allele acting in a
      non-neural musculoskeletal cell type. Marked PARTIAL because skeletal
      muscle cells are not the cartilage or bone lineage that patterns the
      distal skeleton.
- name: Syndromic Multisystem Malformation
  description: >-
    The organism-level structural output that makes this disorder syndromic
    rather than a pure neurodevelopmental disorder: the recognizable dysmorphic
    facial pattern, distal skeletal anomalies of the hands and feet, joint
    hypermobility or contracture, and the minority cardiac and genitourinary
    malformations. Prenatally the same failure can present as microcephaly with
    short femur and intrauterine growth restriction. Because no lineage-specific
    model exists, this node inherits the PROVISIONAL standing of its upstream
    patterning node.
  biological_scale: ORGANISM
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:30639322
    reference_title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The associated features include growth failure, feeding difficulties,
      microcephaly, facial dysmorphism, and various other congenital
      malformations.
    explanation: >-
      Establishes that congenital malformations beyond the nervous system are
      part of the syndrome, which is what this organism-level node collects.
  - reference: PMID:41354990
    reference_title: "Genetic and functional analysis of ZMIZ1 in neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NEDDFSA): insights from muscle cells and signaling pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      supplementary shared characteristics including joint hypermobility or
      joint contracture, eye anomalies, and acral skeletal malformations of
      extremities
    explanation: >-
      Names the non-neurological element of the syndrome — including that joint
      involvement runs in both directions, hypermobility or contracture — in the
      source's own words.
- name: Global Neurodevelopmental Impairment
  description: >-
    The organism-level neurodevelopmental output: early hypotonia and feeding
    difficulty, then delayed motor milestones, poor language acquisition,
    intellectual disability of highly variable severity, and behavioral
    abnormalities including autism and ADHD. Severity is not predictable from
    the variant. A domain-resolved re-analysis of 36 published individuals found
    that alanine-rich-domain variants associate preferentially with intellectual
    disability and motor delay while TPR and proline-rich-domain variants
    associate more with autism plus intellectual disability, but a
    prenatally-ascertained series explicitly found no clear genotype-phenotype
    correlation, and the intrafamilial variability in the one multigenerational
    family shows that genotype alone does not fix outcome.
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:35432459
    reference_title: "A de Novo ZMIZ1 Pathogenic Variant for Neurodevelopmental Disorder With Dysmorphic Facies and Distal Skeletal Anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      global neurodevelopmental delay, early-onset hypotonia, poor overall
      growth, poor speech/language ability
    explanation: >-
      Names the core organism-level neurodevelopmental features in the source's
      own words.
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We find that patients with SNVs in the Alanine-rich domain show strong
      association with diagnosis of ID (62.5%), motor delay (70%), and other
      physical phenotypic manifestations (100%), while ASD diagnosis in
      combination with ID is more strongly associated with mutations in TPR and
      Proline-rich domains.
    explanation: >-
      Supports the domain-resolved phenotype tendencies described in this node.
  - reference: PMID:41918386
    reference_title: "[A fetus with Neurodevelopmental disorders with deformed facial features and distal skeletal abnormalities due to a rare variant of ZMIZ1 gene and literature review]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the main manifestations of patients have included intellectual disability,
      growth retardation and cranio-limb skeletal dysplasia, albeit without
      clear genotype-phenotype correlation
    explanation: >-
      Supports the core manifestations while qualifying the domain-association
      sub-claim: an independent literature synthesis found no clear
      genotype-phenotype correlation, so the domain-phenotype tendencies must
      not be used prognostically. Marked PARTIAL rather than REFUTE because it
      qualifies one statement inside this node, it does not contradict the node
      itself.
genetic:
- name: ZMIZ1
  gene_term:
    preferred_term: ZMIZ1
    term:
      id: hgnc:16493
      label: ZMIZ1
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  association: >-
    Heterozygous ZMIZ1 variants are the sole established cause of NEDDFSA. The
    gene lies at 10q22.3, spans 21 exons, and encodes a 1067-amino-acid
    PIAS-family transcriptional coactivator. Most pathogenic alleles arise de
    novo; germline transmission from a mildly affected parent is documented.
    ZMIZ1 is highly constrained against loss of function in population data
    (observed/expected 0.13).
  notes: >-
    Reported allele classes: missense substitutions (e.g. c.2330G>A p.Gly777Glu
    in the SP-RING/MIZ zinc finger; c.881C>T p.Thr294Ile, c.899C>T p.Thr300Met,
    and c.910G>C p.Ala304Pro in the alanine-rich region), in-frame deletion
    (c.858_875del p.Val288_Ala293del), frameshifting truncations (c.1310delC
    p.Pro437ArgfsX84; c.2633dup p.Gly879ArgfsTer22), a canonical splice-site
    variant causing exon 14 skipping (c.1491+2T>C), and balanced translocations
    disrupting ZMIZ1 or a ZMIZ1 regulatory region. Three caveats attach to the
    c.1491+2T>C splice allele and it should not be read as an established
    pathogenic class: it comes from the dual-genotype PMID:34680978 proband who
    also carries an OTUD6B frameshift over a paternally inherited 0.118 Mb
    8q21.3 deletion involving OTUD6B; it was inherited from her father, whose
    phenotype that report does not characterize; and the 2025 domain-resolved
    re-analysis explicitly excluded splice donor/acceptor variants from its
    curated set. It is listed here as a molecular observation only.
  evidence:
  - reference: PMID:30639322
    reference_title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report 19 subjects with intellectual disability and developmental
      delay carrying variants in ZMIZ1.
    explanation: >-
      The founding cohort establishing ZMIZ1 as the causative gene for this
      syndromic neurodevelopmental disorder.
  - reference: PMID:38117436
    reference_title: "Clinical report and genetic analysis of a novel variant in ZMIZ1 causing neurodevelopmental disorder with dysmorphic factors and distal skeletal anomalies in a Chinese family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The zinc finger MIZ-type containing 1 gene (ZMIZ1) is a causative gene of
      NEDDFSA that encodes a protein inhibitor of the activated STAT-like family
      transcriptional regulator.
    explanation: >-
      Independent confirmation of causation and of the PIAS-like protein family
      assignment.
  - reference: PMID:38686122
    reference_title: "Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      Zmiz1 has an oe-score of 0.13 for loss-of-function mutations (observed
      SNVs 7/expected SNVs 52.1), which indicates that only 13% of the expected
      loss-of-function variants were observed in sampled data.
    explanation: >-
      Quantifies the loss-of-function constraint cited in the association text.
  - reference: PMID:38686122
    reference_title: "Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      an oe-score of 0.64 for missense mutations (observed SNVs 447/expected
      SNVs 699.1)
    explanation: >-
      Companion missense-constraint figure. Missense depletion is real but far
      milder than the loss-of-function depletion, which is why the entry treats
      individual missense alleles as requiring their own functional evidence
      rather than inheriting the gene-level dosage argument.
  - reference: PMID:34680978
    reference_title: "Compound Heterozygote of Point Mutation and Chromosomal Microdeletion Involving OTUD6B Coinciding with ZMIZ1 Variant in Syndromic Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This ZMIZ1 variant yielded exon 14 skipping, as evidenced by mRNA study."
    explanation: >-
      Molecular observation only, documenting a splice-disrupting allele class.
      Marked PARTIAL and explicitly confounded — the proband in this report also
      carries a hemizygous OTUD6B c.873delA over a paternally inherited 0.118 Mb
      8q21.3 deletion involving OTUD6B, so none of her clinical features can be
      attributed to ZMIZ1 alone and no phenotype from this report is curated in
      this entry.
  - reference: PMID:34680978
    reference_title: "Compound Heterozygote of Point Mutation and Chromosomal Microdeletion Involving OTUD6B Coinciding with ZMIZ1 Variant in Syndromic Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a heterozygous ZMIZ1 variant, c.1491 + 2T > C, in the patient and her
      father
    explanation: >-
      Records that this splice allele was inherited rather than de novo, and
      that the transmitting father's phenotype is not characterized in the
      report — a further reason its independent pathogenicity is unestablished.
      Same dual-genotype confound as above.
variants:
- name: NM_020338.4:c.1310delC (p.Pro437ArgfsX84)
  description: >-
    Frameshifting single-base deletion in a proline-rich region, the first
    ZMIZ1 allele shown to be transmitted vertically — carried by an affected
    father and both of his affected sons.
  gene:
    preferred_term: ZMIZ1
    term:
      id: hgnc:16493
      label: ZMIZ1
  clinical_significance: PATHOGENIC
  evidence:
  - reference: PMID:31833199
    reference_title: "Autosomal dominant inheritance in a recently described ZMIZ1-related neurodevelopmental disorder: Case report of siblings and an affected parent."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a novel pathogenic ZMIZ1 variant, c.1310delC (p.Pro437ArgfsX84), causing
      this recently described neurodevelopmental syndrome
    explanation: Names the allele and its pathogenic classification.
- name: NM_020338.4:c.2330G>A (p.Gly777Glu)
  description: >-
    De novo missense substitution in exon 20 affecting the SP-RING/MIZ zinc
    finger domain, predicted to disturb the domain's spatial conformation and
    hence partner binding and SUMO E3 ligase function.
  gene:
    preferred_term: ZMIZ1
    term:
      id: hgnc:16493
      label: ZMIZ1
  clinical_significance: PATHOGENIC
  evidence:
  - reference: PMID:35432459
    reference_title: "A de Novo ZMIZ1 Pathogenic Variant for Neurodevelopmental Disorder With Dysmorphic Facies and Distal Skeletal Anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A de novo heterozygous missense variant (c.2330G > A, p.Gly777Glu, G777E)
      was identified in the exon 20 of ZMIZ1.
    explanation: Names the allele, its de novo origin, and its exon location.
  - reference: PMID:35432459
    reference_title: "A de Novo ZMIZ1 Pathogenic Variant for Neurodevelopmental Disorder With Dysmorphic Facies and Distal Skeletal Anomalies."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      It was predicted that G777E was pathogenic and detrimental to the spatial
      conformation of the MIZ/SP-RING zinc finger domain of ZMIZ1.
    explanation: >-
      In silico structural prediction of the functional consequence. Classified
      COMPUTATIONAL because the claim rests on protein structure prediction, not
      a wet-lab assay.
- name: NM_020338.4:c.858_875del (p.Val288_Ala293del)
  description: >-
    In-frame six-codon deletion altering the alanine-rich domain; reduces mutant
    ZMIZ1 protein abundance in cell-based assays.
  gene:
    preferred_term: ZMIZ1
    term:
      id: hgnc:16493
      label: ZMIZ1
  clinical_significance: PATHOGENIC
  evidence:
  - reference: PMID:38117436
    reference_title: "Clinical report and genetic analysis of a novel variant in ZMIZ1 causing neurodevelopmental disorder with dysmorphic factors and distal skeletal anomalies in a Chinese family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      WES revealed a non-frameshift deletion variant in ZMIZ1 (NM_020338.4:
      c.858_875del, p.Val288_Ala293del), resulting in a structural alteration in
      the protein's alanine-rich domain.
    explanation: Names the allele and localizes it to the alanine-rich domain.
- name: NM_020338.4:c.2633dup (p.Gly879ArgfsTer22)
  description: >-
    De novo frameshifting duplication in the C-terminal transactivation region,
    identified prenatally by whole-exome sequencing on amniotic fluid in a
    fetus with microcephaly, short femur, and intrauterine growth restriction.
  gene:
    preferred_term: ZMIZ1
    term:
      id: hgnc:16493
      label: ZMIZ1
  clinical_significance: PATHOGENIC
  evidence:
  - reference: PMID:41918386
    reference_title: "[A fetus with Neurodevelopmental disorders with deformed facial features and distal skeletal abnormalities due to a rare variant of ZMIZ1 gene and literature review]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      WES revealed that the fetus harbored a de novo heterozygous frameshift
      variant c.2633dup (p.Gly879ArgfsTer22) of the ZMIZ1 gene, which was rated
      as pathogenic (PM2_Supporting+PS2_Supporting+PVS1).
    explanation: >-
      Names the allele, its de novo origin, and its ACMG pathogenic
      classification.
- name: NM_020338.4:c.910G>C (p.Ala304Pro)
  description: >-
    De novo missense substitution in the alanine-rich region. Unusually among
    reported alleles it raises rather than lowers ZMIZ1 mRNA and protein levels
    and mislocalizes the protein, arguing against a uniform haploinsufficiency
    mechanism. The measurement was made on transfected constructs in human
    skeletal muscle cells and HEK293T cells, not endogenous patient cells, so it
    is better read as altered protein stability than as patient-level
    upregulation.
  gene:
    preferred_term: ZMIZ1
    term:
      id: hgnc:16493
      label: ZMIZ1
  clinical_significance: LIKELY_PATHOGENIC
  evidence:
  - reference: PMID:41354990
    reference_title: "Genetic and functional analysis of ZMIZ1 in neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NEDDFSA): insights from muscle cells and signaling pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we identified a novel de novo missense variant c.910G>C (p.A304P) in
      ZMIZ1 in a patient with NEDDFSA.
    explanation: Names the allele, its de novo origin, and the clinical diagnosis.
  - reference: PMID:41354990
    reference_title: "Genetic and functional analysis of ZMIZ1 in neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NEDDFSA): insights from muscle cells and signaling pathways."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Our study identifies a novel likely pathogenic variant in ZMIZ1 associated
      with NEDDFSA.
    explanation: >-
      Sources the likely-pathogenic classification recorded on this variant.
      Classified OTHER because this is a variant-classification statement rather
      than a report of experimental data.
phenotypes:
- category: Neurologic
  name: Global Developmental Delay
  description: >-
    Delay across motor, language, and cognitive domains, present in essentially
    all reported individuals and usually the presenting concern after the
    infantile feeding and tone problems.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:35432459
    reference_title: "A de Novo ZMIZ1 Pathogenic Variant for Neurodevelopmental Disorder With Dysmorphic Facies and Distal Skeletal Anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neurodevelopmental disorder with dysmorphic facies and distal skeletal
      anomalies (NEDDFSA) is a rare syndromic disorder characterized by global
      neurodevelopmental delay
    explanation: >-
      Global neurodevelopmental delay is named as a defining, characterizing
      feature of the entity, supporting the VERY_FREQUENT band.
  - reference: PMID:30639322
    reference_title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report 19 subjects with intellectual disability and developmental
      delay carrying variants in ZMIZ1.
    explanation: >-
      All 19 subjects in the founding cohort had intellectual disability and
      developmental delay, corroborating near-universal occurrence.
- category: Neurologic
  name: Intellectual Disability
  description: >-
    Cognitive impairment of highly variable severity, ranging from severe
    impairment to low-average or normal IQ. Variability is present even within
    a single family carrying the same allele, and one woman with a de novo
    alanine-rich-region variant had only low-average IQ and lived to 52.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  frequency: FREQUENT
  evidence:
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Human genetic studies have linked loss-of-function variants in Zinc Finger
      MIZ-Type Containing 1 (ZMIZ1) to a spectrum of neurodevelopmental
      disorders (NDDs), such as intellectual disability (ID), autism spectrum
      disorders (ASD), and attention-deficit/hyperactivity disorder (ADHD).
    explanation: >-
      Establishes intellectual disability as a core ZMIZ1-associated
      neurodevelopmental outcome.
  - reference: PMID:31833199
    reference_title: "Autosomal dominant inheritance in a recently described ZMIZ1-related neurodevelopmental disorder: Case report of siblings and an affected parent."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Moreover, severity of intellectual disability and eyelid ptosis were
      variable among the affected members.
    explanation: >-
      Direct support for the variable-severity statement, from a family sharing
      one allele.
  - reference: PMID:41039966
    reference_title: "ZMIZ1-Associated Neurodevelopmental Disorder in a 52-Year-Old Woman."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we report a woman with a de novo ZMIZ1 c.899C>T (p.Thr300Met)
      variant, low average IQ
    explanation: >-
      Documents the mild end of the cognitive spectrum, supporting the FREQUENT
      rather than VERY_FREQUENT band for frank intellectual disability.
- category: Neurologic
  name: Hypotonia
  description: >-
    Early-onset, often neonatal or early-infantile hypotonia. Together with poor
    feeding and poor growth it is typically the first manifestation, preceding
    the recognition of developmental delay.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  frequency: FREQUENT
  evidence:
  - reference: PMID:35432459
    reference_title: "A de Novo ZMIZ1 Pathogenic Variant for Neurodevelopmental Disorder With Dysmorphic Facies and Distal Skeletal Anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      global neurodevelopmental delay, early-onset hypotonia, poor overall
      growth, poor speech/language ability
    explanation: >-
      Names early-onset hypotonia among the characterizing features of the
      entity.
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of the individuals with variants affecting the Alanine-rich domain, 100%
      presented facial dysmorphism, 100% presented distal skeletal
      abnormalities, 71% presented growth abnormalities, and 57% presented
      hypotonia and visual abnormalities
    explanation: >-
      Quantitative basis for the FREQUENT band (30-79%). The figure is for the
      alanine-rich-domain subgroup of the domain-resolved subseries, not the
      whole published cohort.
- category: Neurologic
  name: Delayed Speech and Language Development
  description: >-
    Poor language acquisition is one of the most consistent features. Speech
    delay was reported in a majority of individuals in every ZMIZ1 protein
    domain group in the domain-resolved re-analysis.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  frequency: FREQUENT
  evidence:
  - reference: PMID:35432459
    reference_title: "A de Novo ZMIZ1 Pathogenic Variant for Neurodevelopmental Disorder With Dysmorphic Facies and Distal Skeletal Anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      global neurodevelopmental delay, early-onset hypotonia, poor overall
      growth, poor speech/language ability
    explanation: >-
      Poor speech and language ability is named as a characterizing feature of
      the syndrome, alongside the other core neurodevelopmental features.
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The percentage of individuals with variants associated with ID and speech
      delay was high in all domains
    explanation: >-
      Quantitative support that speech delay is frequent regardless of which
      ZMIZ1 domain is affected, justifying the FREQUENT band.
- category: Neurologic
  name: Motor Delay
  description: >-
    Delayed acquisition of motor milestones, typically described as mild.
    Reported in about 70 percent of individuals with alanine-rich-domain
    variants, and less often with variants in other domains.
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  frequency: FREQUENT
  evidence:
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      patients with SNVs in the Alanine-rich domain show strong association with
      diagnosis of ID (62.5%), motor delay (70%), and other physical phenotypic
      manifestations (100%)
    explanation: >-
      Provides the quantitative motor-delay rate underpinning the FREQUENT
      frequency band.
- category: Behavioral
  name: Behavioral Abnormalities
  description: >-
    Behavioral problems are part of the core description of the syndrome and
    were among the primary phenotypic features listed when the disorder was
    first delineated. No published series quantifies "behavioral issues" as a
    single aggregate, so no frequency band is asserted here; the quantified
    behavioral sub-phenotypes (autism, ADHD) carry their own entries and bands.
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:31833199
    reference_title: "Autosomal dominant inheritance in a recently described ZMIZ1-related neurodevelopmental disorder: Case report of siblings and an affected parent."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the primary phenotypic features include intellectual
      disability/developmental delay, seizures, hearing loss, behavioral issues,
      failure to thrive, and various congenital malformations
    explanation: >-
      Lists behavioral issues among the primary phenotypic features of the
      syndrome.
- category: Behavioral
  name: Autism Spectrum Disorder
  description: >-
    Autism is a recurrent ZMIZ1-associated outcome and is preferentially
    associated with variants in the TPR, SPRING/MIZ, and proline-rich domains
    rather than the alanine-rich domain. The forebrain-specific Zmiz1 knockout
    mouse independently reproduces autism-like communication and
    social-interaction phenotypes.
  phenotype_term:
    preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  frequency: FREQUENT
  evidence:
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      while ASD diagnosis in combination with ID is more strongly associated
      with mutations in TPR and Proline-rich domains
    explanation: >-
      Supports both the occurrence of autism in this disorder and the
      domain-preference statement.
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the percent of individuals with variants in TPR and Proline-rich diagnosed
      with ASD (60 and 66%, respectively)
    explanation: >-
      Supplies the quantitative basis for the FREQUENT band (30-79%). The same
      subseries reports 14% for alanine-rich-domain variants, so the rate is
      strongly domain-dependent and these figures come from a
      neurodevelopmentally ascertained literature sample rather than a
      population cohort.
  - reference: PMID:41633496
    reference_title: "Loss of Zmiz1 in Mice Leads to Impaired Cortical Development and Autistic-Like Behaviors."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Zmiz1-knockout mice showed alterations in motor activity, anxiety,
      communication, and social interactions with strong sex differences,
      resembling phenotypes associated with autism.
    explanation: >-
      Model-organism corroboration of the autism phenotype. Kept distinct from
      the human clinical evidence by evidence_source.
- category: Behavioral
  name: Attention Deficit Hyperactivity Disorder
  description: >-
    ADHD is reported among ZMIZ1-associated neurodevelopmental diagnoses, but in
    the domain-resolved subseries it was present in fewer than 30 percent of
    individuals and showed no domain association.
  phenotype_term:
    preferred_term: Attention deficit hyperactivity disorder
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ADHD and the presence of seizures are phenotypes with weaker association
      with variants in these domains (less than 30% of individuals).
    explanation: >-
      Gives the quantitative ceiling (under 30 percent) supporting the
      OCCASIONAL band.
- category: Neurologic
  name: Seizures
  description: >-
    Seizures were listed among the primary features when the syndrome was first
    described but occur in a minority; in the domain-resolved subseries they
    were present in fewer than 30 percent of individuals.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:31833199
    reference_title: "Autosomal dominant inheritance in a recently described ZMIZ1-related neurodevelopmental disorder: Case report of siblings and an affected parent."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the primary phenotypic features include intellectual
      disability/developmental delay, seizures, hearing loss, behavioral issues,
      failure to thrive, and various congenital malformations
    explanation: Lists seizures among the primary features of the syndrome.
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ADHD and the presence of seizures are phenotypes with weaker association
      with variants in these domains (less than 30% of individuals).
    explanation: >-
      Quantifies seizures as a minority feature, justifying OCCASIONAL rather
      than FREQUENT.
- category: Neurologic
  name: Microcephaly
  description: >-
    Reduced head circumference, present from the founding cohort onward and
    detectable prenatally in at least one fetus. It was the most common
    morphological abnormality in the domain-resolved subseries, at 64% of imaged
    individuals. Cortical microcephaly is reproduced in the forebrain-specific
    Zmiz1 knockout mouse, making this one of the best cross-species-validated
    features.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  frequency: FREQUENT
  evidence:
  - reference: PMID:30639322
    reference_title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The associated features include growth failure, feeding difficulties,
      microcephaly, facial dysmorphism, and various other congenital
      malformations.
    explanation: >-
      Names microcephaly among the associated features in the delineating
      cohort.
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common morphological abnormality was microcephaly (64%)"
    explanation: >-
      Quantitative basis for the FREQUENT band (30-79%) among imaged
      individuals.
  - reference: PMID:41633496
    reference_title: "Loss of Zmiz1 in Mice Leads to Impaired Cortical Development and Autistic-Like Behaviors."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Loss of ZMIZ1 led to cortical microcephaly, corpus callosum dysgenesis,
      and abnormal differentiation of upper-layer cortical neurons.
    explanation: >-
      Model-organism corroboration that ZMIZ1 loss is sufficient to cause
      cortical microcephaly.
- category: Neurologic
  name: Abnormal Corpus Callosum Morphology
  description: >-
    Structural abnormality of the corpus callosum, present in 21% of
    MRI-examined individuals in the domain-resolved subseries. This is one of
    the best cross-species-corroborated findings in the disorder: corpus
    callosum dysgenesis is independently reproduced in the forebrain-specific
    Zmiz1 knockout mouse.
  phenotype_term:
    preferred_term: Abnormal corpus callosum morphology
    term:
      id: HP:0001273
      label: Abnormal corpus callosum morphology
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:41633496
    reference_title: "Loss of Zmiz1 in Mice Leads to Impaired Cortical Development and Autistic-Like Behaviors."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Abnormalities in the CC and midline structures have been reported in
      patients with ZMIZ1 mutations
    explanation: >-
      Establishes that callosal abnormality is a human finding in this disorder,
      not only a mouse-model observation. Classified OTHER, not HUMAN_CLINICAL:
      this is a background sentence in a mouse study summarizing other authors'
      patients, so the citing publication generated no human data. The
      quantitative human figure is the PMID:40529245 item below.
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abnormalities in the corpus callosum, with or without heterotopias near
      the ventricular space, were observed in 21% of individuals
    explanation: >-
      Quantitative basis for the OCCASIONAL band (5-29%), with MRI-examined
      individuals as the denominator.
  - reference: PMID:41633496
    reference_title: "Loss of Zmiz1 in Mice Leads to Impaired Cortical Development and Autistic-Like Behaviors."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Loss of ZMIZ1 led to cortical microcephaly, corpus callosum dysgenesis,
      and abnormal differentiation of upper-layer cortical neurons.
    explanation: >-
      Model-organism corroboration that ZMIZ1 loss is sufficient to produce
      callosal dysgenesis.
- category: Neurologic
  name: Gray Matter Heterotopia
  description: >-
    Heterotopic gray matter in the cortical white matter and in periventricular
    locations — the human anatomical counterpart of the neuronal positioning
    defect seen in the overexpression model. It is not a curiosity of one case:
    cortical abnormalities including heterotopias were present in 57% of
    MRI-examined individuals in the domain-resolved subseries, and cerebral
    cortical neuronal heterotopias were confirmed at autopsy in a 52-year-old
    woman with a de novo ZMIZ1 variant.
  phenotype_term:
    preferred_term: Gray matter heterotopia
    term:
      id: HP:0002282
      label: Gray matter heterotopia
  frequency: FREQUENT
  evidence:
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fifty-seven percent of MRI-examined individuals presented abnormalities in
      the cortex, such as heterotopias in the cortical white matter and near the
      ventricles
    explanation: >-
      Quantitative basis for the FREQUENT band (30-79%). Denominator is
      MRI-examined individuals, not all reported patients.
  - reference: PMID:41039966
    reference_title: "ZMIZ1-Associated Neurodevelopmental Disorder in a 52-Year-Old Woman."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional findings seen on autopsy included cerebral cortical neuronal
      heterotopias.
    explanation: >-
      Neuropathological confirmation at autopsy, complementing the imaging-based
      frequency above.
- category: Neurologic
  name: Sleep Disturbance
  description: >-
    Abnormal sleep, reported in 14% of the domain-resolved subseries with no
    association to any particular ZMIZ1 protein domain.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thirty-three percent of patients presented hearing loss and 14% presented
      sleep abnormalities.
    explanation: >-
      Sleep abnormalities in 14% of the subseries maps to the OCCASIONAL band
      (5-29%).
- category: Growth
  name: Failure to Thrive
  description: >-
    Poor overall growth with failure to thrive from early infancy, closely tied
    to the feeding difficulties and hypotonia. Both cited sources name it as a
    core feature but neither quantifies it, so no frequency band is asserted.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:30639322
    reference_title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The associated features include growth failure, feeding difficulties,
      microcephaly, facial dysmorphism, and various other congenital
      malformations.
    explanation: Names growth failure among the associated features.
  - reference: PMID:31833199
    reference_title: "Autosomal dominant inheritance in a recently described ZMIZ1-related neurodevelopmental disorder: Case report of siblings and an affected parent."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the primary phenotypic features include intellectual
      disability/developmental delay, seizures, hearing loss, behavioral issues,
      failure to thrive, and various congenital malformations
    explanation: Lists failure to thrive among the primary phenotypic features.
- category: Gastrointestinal
  name: Feeding Difficulties
  description: >-
    Poor feeding from early infancy, one of the earliest presenting features
    and a contributor to the growth failure. Named as a core feature by the
    delineating cohort but not quantified there, so no frequency band is
    asserted.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:30639322
    reference_title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The associated features include growth failure, feeding difficulties,
      microcephaly, facial dysmorphism, and various other congenital
      malformations.
    explanation: Names feeding difficulties among the associated features.
- category: Growth
  name: Short Stature
  description: >-
    Reduced height, documented in all three affected members of the
    multigenerational family carrying c.1310delC and consistent with the
    general growth failure of the syndrome. A denominator of three affected
    relatives sharing one allele cannot support a population frequency band, so
    none is asserted.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:31833199
    reference_title: "Autosomal dominant inheritance in a recently described ZMIZ1-related neurodevelopmental disorder: Case report of siblings and an affected parent."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While they all show syndromic findings along with short stature and
      intellectual disability, only one child had sensorineural hearing loss.
    explanation: >-
      Documents short stature in all three affected family members. Frequency
      omitted: three relatives sharing a single allele is not a basis for a
      population band.
- category: Growth
  name: Intrauterine Growth Restriction
  description: >-
    Prenatal growth restriction, detected at 30 weeks of gestation together with
    microcephaly and short femur in a fetus with a de novo ZMIZ1 frameshift
    variant. This is the earliest documented manifestation of the disorder.
  phenotype_term:
    preferred_term: Intrauterine growth retardation
    term:
      id: HP:0001511
      label: Intrauterine growth retardation
  evidence:
  - reference: PMID:41918386
    reference_title: "[A fetus with Neurodevelopmental disorders with deformed facial features and distal skeletal abnormalities due to a rare variant of ZMIZ1 gene and literature review]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At 30 weeks of gestation, the fetus was found to have microcephaly, short
      femur and intrauterine growth restriction.
    explanation: >-
      Single prenatal case. Frequency omitted because prenatal ascertainment of
      this disorder is reported only once.
- category: Craniofacial
  name: Facial Dysmorphism
  description: >-
    A dysmorphic facial pattern is one of the two features named in the disorder
    label. Reported elements across the series include downslanted palpebral
    fissures, telecanthus, ptosis and blepharophimosis, and floppy eyelids. No
    single pathognomonic gestalt has been established, and morphological
    alterations of the brain and cranium show no association with any particular
    ZMIZ1 protein domain.
  phenotype_term:
    preferred_term: Abnormal facial shape
    term:
      id: HP:0001999
      label: Abnormal facial shape
  frequency: FREQUENT
  evidence:
  - reference: PMID:30639322
    reference_title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The associated features include growth failure, feeding difficulties,
      microcephaly, facial dysmorphism, and various other congenital
      malformations.
    explanation: Names facial dysmorphism among the associated features.
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ID, speech delay, motor delay, and facial dysmorphism are the most
      frequently observed neurodevelopmental and physical phenotypic
      manifestations in patients with ZMIZ1 mutations
    explanation: >-
      Supports the FREQUENT band. The paper's per-domain facial-dysmorphism
      rates are 100% (alanine-rich), 78% (proline-rich), and 40% (TPR), which
      pool below the 80% VERY_FREQUENT floor, so FREQUENT is the defensible
      band.
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Morphological alterations in the brain and cranium are highly prevalent in
      individuals with missense mutations in ZMIZ1, without any association to
      specific protein domains.
    explanation: >-
      Sources the absence of a domain association. Marked PARTIAL because in the
      source this sentence refers to brain and cranial imaging/head-circumference
      findings, not to facial gestalt, so it does not by itself quantify facial
      dysmorphism.
- category: Craniofacial
  name: Downslanted Palpebral Fissures
  description: >-
    Downward slant of the palpebral fissures, described as part of the
    periocular dysmorphic pattern.
  phenotype_term:
    preferred_term: Downslanted palpebral fissures
    term:
      id: HP:0000494
      label: Downslanted palpebral fissures
  evidence:
  - reference: PMID:39658964
    reference_title: "A novel ZMIZ1 variant associated with NEDDFSA and new ocular features: case report and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      bilateral congenital ptosis and blepharophimosis, floppy eyelids,
      telecanthus, downward palpebral slants, myopia, cryptorchidism, hallux
      valgus and developmental delay
    explanation: >-
      Documents downward palpebral slants in the index case. Frequency omitted —
      the review quantified only ptosis, refractive error, strabismus, and
      amblyopia.
- category: Craniofacial
  name: Telecanthus
  description: >-
    Increased distance between the inner canthi, part of the periocular
    dysmorphic pattern.
  phenotype_term:
    preferred_term: Telecanthus
    term:
      id: HP:0000506
      label: Telecanthus
  evidence:
  - reference: PMID:39658964
    reference_title: "A novel ZMIZ1 variant associated with NEDDFSA and new ocular features: case report and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      bilateral congenital ptosis and blepharophimosis, floppy eyelids,
      telecanthus, downward palpebral slants, myopia, cryptorchidism, hallux
      valgus and developmental delay
    explanation: >-
      Documents telecanthus in the index case. Frequency omitted for the same
      reason as the other unquantified periocular features.
- category: Ophthalmologic
  name: Ptosis
  description: >-
    Drooping of the upper eyelid is the single most common ophthalmic finding in
    this disorder, reported in 35 percent of published cases. It may be
    congenital and bilateral, and its severity varies between members of the
    same family carrying the same allele.
  phenotype_term:
    preferred_term: Ptosis
    term:
      id: HP:0000508
      label: Ptosis
  frequency: FREQUENT
  evidence:
  - reference: PMID:39658964
    reference_title: "A novel ZMIZ1 variant associated with NEDDFSA and new ocular features: case report and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common ophthalmic finding was ptosis (35%)."
    explanation: >-
      Quantitative literature-review frequency of 35 percent maps to the
      FREQUENT band (30-79%).
  - reference: PMID:31833199
    reference_title: "Autosomal dominant inheritance in a recently described ZMIZ1-related neurodevelopmental disorder: Case report of siblings and an affected parent."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Moreover, severity of intellectual disability and eyelid ptosis were
      variable among the affected members.
    explanation: >-
      Independent documentation of ptosis and of its intrafamilial severity
      variability.
- category: Ophthalmologic
  name: Blepharophimosis
  description: >-
    Narrowed horizontal palpebral fissure width, reported with congenital
    bilateral ptosis and floppy eyelids as a newly described ocular feature of
    the syndrome.
  phenotype_term:
    preferred_term: Blepharophimosis
    term:
      id: HP:0000581
      label: Blepharophimosis
  evidence:
  - reference: PMID:39658964
    reference_title: "A novel ZMIZ1 variant associated with NEDDFSA and new ocular features: case report and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a pediatric patient presenting with multiple anomalies including bilateral
      congenital ptosis and blepharophimosis
    explanation: >-
      Documents blepharophimosis. Frequency omitted because the paper describes
      it as a previously undescribed feature seen in one patient.
- category: Ophthalmologic
  name: Myopia
  description: >-
    Refractive error is common in this disorder; myopia was found in 20 percent
    of published cases and hyperopia in 12 percent. High myopia was documented
    in one adult.
  phenotype_term:
    preferred_term: Myopia
    term:
      id: HP:0000545
      label: Myopia
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:39658964
    reference_title: "A novel ZMIZ1 variant associated with NEDDFSA and new ocular features: case report and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Refractive error was common (myopia in 20%, hyperopia in 12%)."
    explanation: >-
      Myopia in 20 percent of cases maps to the OCCASIONAL band (5-29%).
  - reference: PMID:41039966
    reference_title: "ZMIZ1-Associated Neurodevelopmental Disorder in a 52-Year-Old Woman."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a woman with a de novo ZMIZ1 c.899C>T (p.Thr300Met) variant, low average
      IQ, high myopia
    explanation: Independent documentation of myopia, at the severe end.
- category: Ophthalmologic
  name: Strabismus
  description: Ocular misalignment, reported in 12 percent of published cases.
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:39658964
    reference_title: "A novel ZMIZ1 variant associated with NEDDFSA and new ocular features: case report and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other findings included strabismus (12%) and amblyopia (16%)."
    explanation: >-
      Strabismus in 12 percent of cases maps to the OCCASIONAL band (5-29%).
- category: Ophthalmologic
  name: Amblyopia
  description: >-
    Reduced vision not correctable by refraction, reported in 16 percent of
    published cases and often accompanying the ptosis and strabismus.
  phenotype_term:
    preferred_term: Amblyopia
    term:
      id: HP:0000646
      label: Amblyopia
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:39658964
    reference_title: "A novel ZMIZ1 variant associated with NEDDFSA and new ocular features: case report and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other findings included strabismus (12%) and amblyopia (16%)."
    explanation: >-
      Amblyopia in 16 percent of cases maps to the OCCASIONAL band (5-29%).
- category: Musculoskeletal
  name: Distal Skeletal Anomalies of the Hands and Feet
  description: >-
    Skeletal anomalies of the hands and feet are the second feature named in the
    disorder label and one of its defining characteristics. Reported elements
    include hallux valgus and, prenatally, short femur; across the wider series
    the pattern is described as cranio-limb skeletal dysplasia.
  phenotype_term:
    preferred_term: Abnormal digit morphology
    term:
      id: HP:0011297
      label: Abnormal digit morphology
  frequency: FREQUENT
  evidence:
  - reference: PMID:35432459
    reference_title: "A de Novo ZMIZ1 Pathogenic Variant for Neurodevelopmental Disorder With Dysmorphic Facies and Distal Skeletal Anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      additional common phenotypes such as eye anomalies, joint hypermobility,
      and skeletal anomalies of the hands and feet
    explanation: >-
      Names skeletal anomalies of the hands and feet as a common, characterizing
      phenotype of the entity.
  - reference: PMID:41918386
    reference_title: "[A fetus with Neurodevelopmental disorders with deformed facial features and distal skeletal abnormalities due to a rare variant of ZMIZ1 gene and literature review]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the main manifestations of patients have included intellectual disability,
      growth retardation and cranio-limb skeletal dysplasia
    explanation: >-
      Corroborates limb skeletal dysplasia as a main manifestation across the
      published series.
- category: Musculoskeletal
  name: Hallux Valgus
  description: >-
    Lateral deviation of the great toe, one of the specific distal foot
    anomalies documented in this syndrome.
  phenotype_term:
    preferred_term: Hallux valgus
    term:
      id: HP:0001822
      label: Hallux valgus
  evidence:
  - reference: PMID:39658964
    reference_title: "A novel ZMIZ1 variant associated with NEDDFSA and new ocular features: case report and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      telecanthus, downward palpebral slants, myopia, cryptorchidism, hallux
      valgus and developmental delay
    explanation: >-
      Documents hallux valgus. Frequency omitted — reported in individual cases
      rather than quantified across the series.
- category: Musculoskeletal
  name: Joint Hypermobility
  description: >-
    Increased joint laxity, named among the common phenotypes characterizing the
    entity, and documented in individual cases alongside hip dysplasia. Note
    that joint involvement in NEDDFSA is bidirectional — the syndrome
    description pairs hypermobility with contracture, which is curated
    separately.
  phenotype_term:
    preferred_term: Joint hypermobility
    term:
      id: HP:0001382
      label: Joint hypermobility
  frequency: FREQUENT
  evidence:
  - reference: PMID:35432459
    reference_title: "A de Novo ZMIZ1 Pathogenic Variant for Neurodevelopmental Disorder With Dysmorphic Facies and Distal Skeletal Anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      additional common phenotypes such as eye anomalies, joint hypermobility,
      and skeletal anomalies of the hands and feet
    explanation: >-
      Names joint hypermobility explicitly as a common phenotype of the
      disorder.
- category: Musculoskeletal
  name: Joint Contracture
  description: >-
    Fixed limitation of joint movement. Joint involvement in this disorder runs
    in both directions: the syndrome description explicitly pairs hypermobility
    with contracture, and an 11-month-old proband presented with bilateral hand
    contractures together with congenital vertical talus and bilateral auricular
    deformity.
  phenotype_term:
    preferred_term: Joint contracture
    term:
      id: HP:0034392
      label: Joint contracture
  evidence:
  - reference: PMID:41354990
    reference_title: "Genetic and functional analysis of ZMIZ1 in neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NEDDFSA): insights from muscle cells and signaling pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      supplementary shared characteristics including joint hypermobility or
      joint contracture, eye anomalies, and acral skeletal malformations of
      extremities
    explanation: >-
      Establishes contracture as a recognized part of the NEDDFSA joint
      phenotype, not merely the opposite of the curated hypermobility.
  - reference: PMID:41354990
    reference_title: "Genetic and functional analysis of ZMIZ1 in neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NEDDFSA): insights from muscle cells and signaling pathways."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      bilateral auricular deformity (Fig. 1b), bilateral hand contractures
      (Fig. 1c–e), congenital vertical talus (Fig. 1f), developmental delay,
      hearing impairment, and bilateral cryptorchidism
    explanation: >-
      Documents bilateral hand contractures in an individual proband. Frequency
      omitted because this is a single case.
- category: Musculoskeletal
  name: Hip Dysplasia
  description: >-
    Developmental dysplasia of the hip, bilateral in the reported Chinese
    proband and detected in infancy through asymmetric skin creases of the
    lower limbs.
  phenotype_term:
    preferred_term: Hip dysplasia
    term:
      id: HP:0001385
      label: Hip dysplasia
  evidence:
  - reference: PMID:35432459
    reference_title: "A de Novo ZMIZ1 Pathogenic Variant for Neurodevelopmental Disorder With Dysmorphic Facies and Distal Skeletal Anomalies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a 5-year-old girl with mild development delay, mild intellectual
      disability, bilateral hip dysplasia, joint hypermobility, amblyopia in
      both eyes, strabismus in the right eye, and dysmorphic facial features
    explanation: >-
      Documents bilateral hip dysplasia in an individual case. Frequency omitted
      because this is a single-case observation.
- category: Auditory
  name: Sensorineural Hearing Loss
  description: >-
    Sensorineural hearing impairment was among the primary features listed when
    the syndrome was delineated and was found in about a third of individuals in
    the domain-resolved subseries, with no domain association. It is variable
    even within a family: only one of two affected brothers sharing the same
    allele had it.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  frequency: FREQUENT
  evidence:
  - reference: PMID:40529245
    reference_title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thirty-three percent of patients presented hearing loss and 14% presented
      sleep abnormalities.
    explanation: >-
      Hearing loss in 33 percent of the subseries maps to the FREQUENT band
      (30-79%).
  - reference: PMID:31833199
    reference_title: "Autosomal dominant inheritance in a recently described ZMIZ1-related neurodevelopmental disorder: Case report of siblings and an affected parent."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While they all show syndromic findings along with short stature and
      intellectual disability, only one child had sensorineural hearing loss.
    explanation: >-
      Specifies the hearing loss as sensorineural and documents its
      intrafamilial variability.
- category: Cardiovascular
  name: Congenital Heart Disease
  description: >-
    Structural cardiac defects occur in a minority of individuals and were
    reported both in an infant with an alanine-rich in-frame deletion and in an
    adult with an alanine-rich missense variant. Both sources are single case
    reports with no denominator, so no frequency band is asserted.
  phenotype_term:
    preferred_term: Abnormal heart morphology
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: PMID:38117436
    reference_title: "Clinical report and genetic analysis of a novel variant in ZMIZ1 causing neurodevelopmental disorder with dysmorphic factors and distal skeletal anomalies in a Chinese family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The patient was a 6-month-old male infant who exhibited dysmorphic facial
      features, neurodevelopmental abnormalities, congenital heart disease, and
      previously unreported genitourinary system anomalies.
    explanation: Documents congenital heart disease in a ZMIZ1-only proband.
  - reference: PMID:41039966
    reference_title: "ZMIZ1-Associated Neurodevelopmental Disorder in a 52-Year-Old Woman."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      craniofacial dysmorphisms, genitourinary anomalies, cardiac defects, lower
      limb deformities, and chronic pain
    explanation: >-
      Independent documentation of cardiac defects in a second ZMIZ1-only
      individual.
- category: Genitourinary
  name: Genitourinary Anomalies
  description: >-
    Anomalies of the genitourinary system, first reported as a novel feature in
    a 6-month-old infant and independently documented in an adult woman.
    Cryptorchidism has been reported separately in a male patient. Both sources
    are single case reports with no denominator, so no frequency band is
    asserted.
  phenotype_term:
    preferred_term: Abnormality of the genitourinary system
    term:
      id: HP:0000119
      label: Abnormality of the genitourinary system
  evidence:
  - reference: PMID:38117436
    reference_title: "Clinical report and genetic analysis of a novel variant in ZMIZ1 causing neurodevelopmental disorder with dysmorphic factors and distal skeletal anomalies in a Chinese family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      congenital heart disease, and previously unreported genitourinary system
      anomalies
    explanation: First report of genitourinary anomalies in this disorder.
  - reference: PMID:41039966
    reference_title: "ZMIZ1-Associated Neurodevelopmental Disorder in a 52-Year-Old Woman."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      craniofacial dysmorphisms, genitourinary anomalies, cardiac defects, lower
      limb deformities, and chronic pain
    explanation: >-
      Independent confirmation in a second individual, establishing this as a
      recurrent rather than isolated finding.
- category: Genitourinary
  name: Cryptorchidism
  description: >-
    Undescended testis, documented in a male patient with a de novo ZMIZ1
    alanine-rich-region variant.
  phenotype_term:
    preferred_term: Cryptorchidism
    term:
      id: HP:0000028
      label: Cryptorchidism
  evidence:
  - reference: PMID:39658964
    reference_title: "A novel ZMIZ1 variant associated with NEDDFSA and new ocular features: case report and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      telecanthus, downward palpebral slants, myopia, cryptorchidism, hallux
      valgus and developmental delay
    explanation: >-
      Documents cryptorchidism in the index case. Frequency omitted because it
      is a single-case observation in a male patient.
- category: Gastrointestinal
  name: Hirschsprung Disease
  description: >-
    Aganglionic megacolon, reported once in a patient with a de novo pathogenic
    ZMIZ1 variant and developmental delay. This is a candidate spectrum
    expansion rather than an established feature: the primary report is a single
    case report in a journal not indexed in PubMed, and the observation reaches
    this entry only as a secondary citation.
  phenotype_term:
    preferred_term: Aganglionic megacolon
    term:
      id: HP:0002251
      label: Aganglionic megacolon
  evidence:
  - reference: PMID:38686122
    reference_title: "Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      a case study revealed a de novo pathogenic variant in ZMIZ1 in a patient
      with developmental delay and Hirschsprung Disease
    explanation: >-
      Marked PARTIAL, and classified OTHER rather than HUMAN_CLINICAL, because
      this is a background sentence in a non-clinical study relaying a single
      primary case from another group (Valind et al. 2021, J Pediatr Surg Case
      Rep 71:101889, doi:10.1016/j.epsc.2021.101889). That primary report is not
      PubMed-indexed and has no retrievable abstract, so the claim could not be
      verified at source. Frequency omitted.
animal_models:
- species: Mus musculus
  genotype: Forebrain-specific conditional Zmiz1 knockout
  category: Conditional loss-of-function mouse model of ZMIZ1 syndrome
  description: >-
    The principal in vivo loss-of-function model of this disorder, reported in
    PMID:41633496. It reproduces cortical microcephaly, corpus callosum
    dysgenesis, and abnormal differentiation of upper-layer cortical neurons,
    together with autism-like behavioral changes in motor activity, anxiety,
    communication, and social interaction with strong sex differences. RNA-seq
    plus ChIP-seq identified Lhx2, Auts2, and EfnB2 as ZMIZ1-regulated
    neurodevelopmental targets, and reactivation of the ephrin-B2 pathway
    rescued the dendritic outgrowth deficit — the first mechanistic rescue
    reported for this disorder. It models the "Impaired Cortical Neurogenesis,
    Neuronal Differentiation, and Positioning" and "Dysregulated Developmental
    Transcriptional Programs" pathophysiology nodes. Face validity for the
    neurological arm is good, but because Zmiz1 deletion is restricted to
    forebrain the model cannot address the craniofacial, distal skeletal,
    cardiac, or genitourinary features, which therefore remain unmodeled.
  associated_phenotypes:
  - Cortical microcephaly
  - Corpus callosum dysgenesis
  - Abnormal differentiation of upper-layer cortical neurons
  - Autism-like social and communication deficits
  evidence:
  - reference: PMID:41633496
    reference_title: "Loss of Zmiz1 in Mice Leads to Impaired Cortical Development and Autistic-Like Behaviors."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We generated forebrain-specific Zmiz1 mutant mice (Zmiz1-knockout) to
      assess ZMIZ1 function in cortical development.
    explanation: Describes the model construction.
  - reference: PMID:41633496
    reference_title: "Loss of Zmiz1 in Mice Leads to Impaired Cortical Development and Autistic-Like Behaviors."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Loss of ZMIZ1 led to cortical microcephaly, corpus callosum dysgenesis,
      and abnormal differentiation of upper-layer cortical neurons.
    explanation: >-
      Establishes the structural brain phenotypes recapitulated by the model.
- species: Mus musculus
  genotype: In utero electroporation of patient ZMIZ1 mutant alleles into embryonic cortex
  category: Acute somatic overexpression model of patient alleles
  description: >-
    An acute somatic model, reported in PMID:30639322, in which patient-derived
    ZMIZ1 mutant alleles were introduced into cortical progenitors of the
    embryonic mouse ventricular zone by in utero electroporation. Mutant alleles
    produced abnormal pyramidal neuron morphology, polarization, and
    positioning. This was the in vivo evidence that established the
    pathogenicity of the human alleles and models the "Impaired Cortical
    Neurogenesis, Neuronal Differentiation, and Positioning" node. Interpretive
    caveat: it is an overexpression paradigm, not an endogenous knock-in, so it
    cannot distinguish loss of function from dominant-negative or
    gain-of-function effects; the conditional knockout above is the
    complementary loss-of-function test.
  associated_phenotypes:
  - Abnormal pyramidal neuron morphology and polarization
  - Impaired neuronal positioning in the developing cortex
  evidence:
  - reference: PMID:30639322
    reference_title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In vivo, overexpression of ZMIZ1 mutant alleles in developing mouse brains
      using in utero electroporation resulted in abnormal pyramidal neuron
      morphology, polarization, and positioning
    explanation: >-
      Describes the model and its principal readout, linking human alleles to a
      cortical developmental defect.
diagnosis:
- name: Molecular Genetic Testing
  description: >-
    Diagnosis rests on identification of a heterozygous pathogenic ZMIZ1 variant.
    In practice every reported diagnosis has come from exome sequencing or a
    broad multigene panel rather than from targeted single-gene testing, because
    the clinical gestalt is not specific enough to prompt a directed test.
    Chromosomal microarray and structural-variant analysis remain relevant
    because balanced translocations disrupting ZMIZ1 or its regulatory region
    also cause the disorder and are invisible to standard exome analysis. Trio
    testing is preferred: most variants are de novo, and where they are not, the
    transmitting parent may be only mildly affected and requires targeted
    testing to identify.
  evidence:
  - reference: PMID:41918386
    reference_title: "[A fetus with Neurodevelopmental disorders with deformed facial features and distal skeletal abnormalities due to a rare variant of ZMIZ1 gene and literature review]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Whole-exome sequencing (WES) was carried out on the amniotic fluid and
      parental peripheral blood samples, and candidate variants was verified by
      Sanger sequencing.
    explanation: >-
      Illustrates the trio exome-plus-Sanger workflow, here applied prenatally.
  - reference: PMID:30639322
    reference_title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      2 subjects had a balanced translocation disrupting ZMIZ1 or involving a
      regulatory region of ZMIZ1
    explanation: >-
      Justifies retaining cytogenomic/structural testing alongside sequencing,
      since translocation and regulatory lesions also cause the disorder.
  - reference: PMID:31833199
    reference_title: "Autosomal dominant inheritance in a recently described ZMIZ1-related neurodevelopmental disorder: Case report of siblings and an affected parent."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "parental testing to identify a mildly affected parent is needed"
    explanation: >-
      Supports the recommendation for parental testing rather than assuming de
      novo occurrence.
differential_diagnoses:
- name: Neurodevelopmental Disorder with Dysmorphic Facies and Distal Limb Anomalies (NEDDFL, BPTF)
  disease_term:
    preferred_term: BPTF-related neurodevelopmental disorder (NEDDFL)
    term:
      id: MONDO:0060596
      label: neurodevelopmental disorder with dysmorphic facies and distal limb anomalies
  description: >-
    The single most important label hazard for this entry. NEDDFL
    (MONDO:0060596, OMIM:617755) is caused by heterozygous variants in BPTF
    (HGNC:3581), a bromodomain PHD finger chromatin-remodeling transcription
    factor. Its name differs from this disorder's by one word — "limb" versus
    "skeletal" — and both are autosomal dominant syndromic neurodevelopmental
    disorders with developmental delay, dysmorphic facies, microcephaly, and
    distal anomalies. They are separate entities with separate causal genes and
    must never be pooled.
  distinguishing_features:
  - >-
    Molecular: BPTF (HGNC:3581), a bromodomain/PHD-finger chromatin remodeler,
    versus ZMIZ1 (hgnc:16493), a PIAS-family SUMO E3 ligase and transcriptional
    coactivator. Different genes, different chromosomes, different protein
    families. This is the definitive discriminator and requires sequencing.
  - >-
    Nomenclature: "distal LIMB anomalies" (NEDDFL, BPTF, OMIM:617755) versus
    "distal SKELETAL anomalies" (NEDDFSA, ZMIZ1, OMIM:618659). Curators and
    automated literature-mining tools must key on the gene or the OMIM number,
    never on the disease name alone.
  - >-
    Clinical emphasis: postnatal microcephaly and speech delay are prominent in
    NEDDFL, whereas the ZMIZ1 disorder is anchored on early hypotonia, poor
    feeding and growth failure, joint hypermobility, and ptosis as the leading
    ocular sign.
  notes: >-
    No shared mechanism justifies pooling evidence between these entities: BPTF
    acts through the NURF chromatin-remodeling complex, ZMIZ1 through
    PIAS-family coactivation of NOTCH1, AR, p53, and SMAD3/4. Any DR-sourced
    claim about a "NEDDF-" disorder must be checked against the gene before use.
    The identity of MONDO:0060596 with BPTF and OMIM:617755 was verified with
    OAK during the NEC preflight for this entry.
- name: OTUD6B-Related Neurodevelopmental Disorder (IDDFSDA)
  disease_term:
    preferred_term: OTUD6B-related intellectual developmental disorder
    term:
      id: MONDO:0044319
      label: intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies
  description: >-
    An autosomal recessive syndromic intellectual disability caused by biallelic
    OTUD6B variants, sharing facial dysmorphism, distal limb anomalies, and
    seizures with this disorder. Crucially, the two are not merely confusable:
    PMID:34680978 reports a single 5-year-old girl who genuinely carries
    disease-relevant variants at BOTH loci — a hemizygous OTUD6B c.873delA over
    a paternally inherited 8q21.3 whole-gene deletion, together with a
    heterozygous ZMIZ1 c.1491+2T>C splice variant shown by mRNA study to skip
    exon 14. Finding a ZMIZ1 variant therefore does not exclude OTUD6B disease,
    and vice versa.
  distinguishing_features:
  - >-
    Inheritance: OTUD6B disease is autosomal recessive (biallelic), this
    disorder is autosomal dominant (heterozygous). This alone usually separates
    them on a trio exome.
  - >-
    Molecular: OTUD6B is a deubiquitinase; ZMIZ1 is a transcriptional
    coactivator and SUMO E3 ligase. No shared mechanism, so evidence must not be
    pooled across the two entries.
  notes: >-
    Attribution rule applied in this entry: no phenotype from the dual-genotype
    PMID:34680978 proband is curated here, and every citation to that paper is
    marked with the confound explicitly. The reciprocal caveat is recorded in
    the dismech OTUD6B-Related Neurodevelopmental Disorder entry, which curates
    that proband's Williams syndrome-like features (periorbital edema, hanging
    cheek, long and smooth philtrum) and polydactyly with supports PARTIAL for
    the same reason.
  evidence:
  - reference: PMID:34680978
    reference_title: "Compound Heterozygote of Point Mutation and Chromosomal Microdeletion Involving OTUD6B Coinciding with ZMIZ1 Variant in Syndromic Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The OTUD6B and ZMIZ1 genes were recently identified as causes of syndromic
      intellectual disability (ID) with shared phenotypes of facial dysmorphism,
      distal limb anomalies, and seizure disorders.
    explanation: >-
      States the phenotypic overlap that makes OTUD6B disease a differential, in
      the authors' own words.
  - reference: PMID:34680978
    reference_title: "Compound Heterozygote of Point Mutation and Chromosomal Microdeletion Involving OTUD6B Coinciding with ZMIZ1 Variant in Syndromic Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      OTUD6B- and ZMIZ1-related ID are inherited in autosomal recessive and
      autosomal dominant patterns, respectively.
    explanation: >-
      Sources the inheritance-mode discriminator between the two entities.
- name: PRR12-Related Neuroocular Syndrome
  disease_term:
    preferred_term: PRR12-related neuroocular syndrome
    term:
      id: MONDO:0971007
      label: neuroocular syndrome 1
  description: >-
    A separate autosomal dominant neurodevelopmental disorder caused by PRR12
    haploinsufficiency, relevant here for a specific structural reason: the
    balanced translocation t(10;19)(q22.3;q13.33) that first drew attention to
    the ZMIZ1 locus simultaneously disrupts PRR12, producing reciprocal
    ZMIZ1-PRR12 and PRR12-ZMIZ1 fusion genes. Translocation probands therefore
    carry lesions at two independent neurodevelopmental disease genes.
  distinguishing_features:
  - >-
    Molecular: PRR12 (19q13.33), a proline-rich chromatin-associated nuclear
    protein, versus ZMIZ1 (10q22.3), a PIAS-family coactivator.
  - >-
    Clinical: the PRR12 disorder is defined by its ocular phenotype across the
    anophthalmia-microphthalmia-coloboma spectrum and anterior segment
    dysgenesis. The ZMIZ1 ocular phenotype is quite different — eyelid and
    refractive findings (ptosis, blepharophimosis, myopia, strabismus,
    amblyopia), not MAC-spectrum globe malformation.
  notes: >-
    Curation rule applied here: cases whose only lesion is a t(10;19)
    translocation disrupting both genes are not used as clean ZMIZ1 phenotype
    evidence in this entry.
treatments:
- name: Multidisciplinary Supportive and Developmental Care
  description: >-
    No disease-modifying therapy exists. Management is entirely supportive and
    anticipatory, directed at the individual features: nutritional support for
    the infantile feeding difficulty and growth failure, early intervention with
    physical, occupational, and speech therapy for the hypotonia and
    developmental delay, ophthalmological assessment and management (ptosis
    repair, refractive correction, amblyopia therapy) given that ptosis and
    refractive error are the leading eye findings, audiological surveillance
    because sensorineural hearing loss affects roughly a third of individuals,
    orthopaedic assessment for hip dysplasia and distal limb anomalies, seizure
    management where relevant, and cardiac and renal imaging given the reported
    congenital heart and genitourinary anomalies.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  therapeutic_modality: OTHER
  notes: >-
    Modality: recorded as OTHER, not BEHAVIORAL. This treatment is a
    multidisciplinary bundle spanning nutritional support, physical/occupational/
    speech therapy, ophthalmic surgery (ptosis repair) and refractive correction,
    hearing devices, and orthopaedic and cardiac/renal surveillance. Those span
    the BEHAVIORAL, SURGERY, and DEVICE modalities at once, so no single platform
    value is truthful; per the single-value discipline in CLAUDE.md the honest
    tag is OTHER. Splitting this into per-modality treatments would be a
    reasonable future refinement once disease-specific management evidence exists.

    This management framework is assembled from the phenotype set rather than
    from a published management guideline: no GeneReviews chapter, consensus
    statement, or natural-history study exists for NEDDFSA, and no clinical
    trial has been registered. It is therefore standard-of-care extrapolation,
    which is why it carries no evidence items — no publication states these
    recommendations for this disorder, and fabricating a citation would be worse
    than recording the gap. See the neddfsa_no_management_guideline discussion.
- name: Genetic Counseling
  description: >-
    Counseling should cover the autosomal dominant mechanism, the 50 percent
    recurrence risk for an affected parent, and the low but non-zero recurrence
    risk after an apparently de novo case (parental germline mosaicism cannot be
    excluded). Testing both parents is specifically indicated rather than
    optional, because a transmitting parent may be only mildly affected and
    would otherwise be missed — the family reported with c.1310delC included an
    affected father identified only after his sons were diagnosed. Prenatal
    diagnosis by exome sequencing on amniotic fluid has been performed
    successfully.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  notes: >-
    therapeutic_modality is deliberately omitted. CLAUDE.md's mechanical
    backfill table explicitly excludes NCIT:C15240 (Genetic Counseling) from
    modality assignment on the grounds that such actions are "not
    platform-classifiable"; tagging it BEHAVIORAL would misfile an informational
    and reproductive-risk intervention as a behavioral therapy.
  evidence:
  - reference: PMID:31833199
    reference_title: "Autosomal dominant inheritance in a recently described ZMIZ1-related neurodevelopmental disorder: Case report of siblings and an affected parent."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "parental testing to identify a mildly affected parent is needed"
    explanation: >-
      Directly supports the recommendation that both parents be tested rather
      than assuming de novo occurrence.
  - reference: PMID:41918386
    reference_title: "[A fetus with Neurodevelopmental disorders with deformed facial features and distal skeletal abnormalities due to a rare variant of ZMIZ1 gene and literature review]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic testing has enabled accurate prenatal diagnosis and provided
      evidence for genetic counseling and reproductive guidance of this family.
    explanation: >-
      Supports the availability and utility of prenatal diagnosis and genetic
      counseling in this disorder.
discussions:
- discussion_id: neddfsa_no_management_guideline
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    What is the natural history of NEDDFSA across the lifespan, and what
    surveillance schedule should ZMIZ1-related disorder actually follow?
  rationale: >-
    No GeneReviews chapter, consensus management statement, natural-history
    study, or registered clinical trial exists for this disorder. The management
    framework recorded in this entry is standard-of-care extrapolation from the
    phenotype list, not evidence-based guidance, and is deliberately left
    without evidence items for that reason. The single published adult (a woman
    who died unexpectedly at 52 and had chronic pain and lower limb deformities)
    is currently the only window onto adult outcome, so even basic questions —
    does hearing loss progress, does the hip and foot pathology need
    surveillance, is there excess mortality — are unanswered.
  attaches_to:
  - pathophysiology#Global Neurodevelopmental Impairment
  proposed_experiments:
  - experiment_id: exp_neddfsa_prospective_registry
    name: Prospective international ZMIZ1 natural-history registry
    description: >-
      Assemble a prospective international ZMIZ1 registry with standardized
      developmental, ophthalmological, audiological, orthopaedic, cardiac, and
      renal assessment at fixed ages, powered to produce an evidence-based
      surveillance schedule and a natural-history curve extending into
      adulthood.
  - experiment_id: exp_neddfsa_hpo_rephenotyping
    name: Systematic HPO re-phenotyping of all published cases
    description: >-
      Systematically re-code every published ZMIZ1 case against HPO from the
      primary descriptions, replacing the current mixture of narrative
      descriptions and partially overlapping literature reviews with computable,
      denominator-anchored feature frequencies.
- discussion_id: neddfsa_allele_mechanism_direction
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Do all pathogenic ZMIZ1 alleles act by loss of coactivator function, or do
    some act by dominant-negative or gain-of-function mechanisms?
  rationale: >-
    The functional data point in opposite directions depending on the allele. An
    alanine-rich in-frame deletion (p.Val288_Ala293del) reduced ZMIZ1 protein
    abundance, consistent with haploinsufficiency, while a nearby alanine-rich
    missense allele (p.Ala304Pro) increased ZMIZ1 mRNA and protein and
    mislocalized the protein, which is not a loss-of-dosage phenotype.
    Gene-level constraint (loss-of-function observed/expected 0.13) supports
    dosage sensitivity but says nothing about individual missense alleles. The
    in vivo evidence that established pathogenicity used overexpression of
    mutant alleles by in utero electroporation, a paradigm that cannot separate
    loss of function from dominant-negative action. Resolving this matters
    directly for therapeutic strategy: dosage restoration would help only the
    haploinsufficient alleles.
  attaches_to:
  - pathophysiology#Heterozygous ZMIZ1 Variant
  - pathophysiology#Impaired PIAS-Family Coactivator Function
  proposed_experiments:
  - experiment_id: exp_neddfsa_isogenic_ipsc_allele_series
    name: Isogenic heterozygous knock-in iPSC allele series
    description: >-
      Generate isogenic heterozygous knock-in human iPSC lines for
      representative alleles from each domain (TPR, alanine-rich, proline-rich,
      SP-RING/MIZ, transactivation) alongside a heterozygous null, differentiate
      to cortical neurons, and compare transcriptomes. Null-like profiles
      indicate loss of function; profiles diverging from the null indicate
      dominant-negative or gain-of-function action.
  - experiment_id: exp_neddfsa_endogenous_coactivation_assays
    name: Endogenous-level coactivation and SUMO ligase assays per allele class
    description: >-
      Assay NOTCH1 and androgen receptor coactivation and SUMO E3 ligase
      activity for each allele class at endogenous expression levels rather than
      by overexpression, so that direction of effect is not an artifact of the
      assay.
- discussion_id: neddfsa_skeletal_arm_unmodeled
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Is the craniofacial and distal skeletal phenotype that names this disorder
    actually caused by ZMIZ1 loss in skeletal tissue, given that the only in vivo
    model deletes Zmiz1 exclusively in forebrain and therefore cannot develop it?
  rationale: >-
    The mechanism chain for the neurological arm is well supported in vivo, but
    the arm that gives the disorder its name is not modeled at all. The
    forebrain-specific Zmiz1 conditional knockout by construction cannot produce
    craniofacial or limb skeletal phenotypes, and the in utero electroporation
    model is CNS-only. The single functional study in a non-neural cell type
    used human skeletal muscle cells, which are neither the cartilage nor the
    osteoblast lineage that patterns the distal skeleton, and it reported
    increased proliferation and migration — a direction of effect that is not
    obviously connected to the clinical skeletal findings. This is a genuine
    model-to-human validity gap rather than an absence of evidence, which is why
    the Disrupted Craniofacial and Distal Skeletal Patterning node is marked
    PROVISIONAL.
  attaches_to:
  - pathophysiology#Disrupted Craniofacial and Distal Skeletal Patterning
  proposed_experiments:
  - experiment_id: exp_neddfsa_crest_and_limb_conditional_ko
    name: Neural-crest and limb-mesenchyme conditional Zmiz1 knockouts
    description: >-
      Generate a cranial-neural-crest-specific and a limb-mesenchyme-specific
      Zmiz1 conditional knockout and phenotype the craniofacial skeleton and
      autopod for the anomalies reported in patients, establishing whether the
      skeletal arm is cell-autonomous to those lineages.
  - experiment_id: exp_neddfsa_crest_target_profiling
    name: ZMIZ1 target profiling in human iPSC-derived crest and limb mesenchyme
    description: >-
      Profile ZMIZ1 chromatin occupancy and NOTCH1/SMAD target-gene output in
      human iPSC-derived cranial neural crest cells and limb-bud-like mesenchyme
      carrying patient alleles, to identify the skeletal target genes that are
      currently unknown.
datasets:
- accession: GEO:GSE225435
  title: RNA sequencing on Postnatal day (P) 7 wildtype and Zmiz1-Knockout cortex
  description: >-
    Cortical RNA-seq from the Emx1-Cre forebrain-specific Zmiz1 knockout, the
    primary transcriptomic dataset behind the "Dysregulated Developmental
    Transcriptional Programs" node. It identified 114 differentially expressed
    genes at postnatal day 7, with downregulated genes enriched for forebrain
    development, axon development, and neuron differentiation.
  data_type: BULK_RNA_SEQ
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  genes:
  - preferred_term: ZMIZ1
    term:
      id: hgnc:16493
      label: ZMIZ1
  publication: PMID:41633496
  evidence:
  - reference: GEO:GSE225435
    reference_title: "RNA sequencing on Postnatal day (P) 7 wildtype and Zmiz1-Knockout cortex"
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We found 114 differentially expressed genes of which 35 genes were
      upregulated while 69 genes were downregulated. Downregulated genes were
      enriched in biological processes such as forebrain deveopment, axon
      development, neuron differentiation etc.
    explanation: >-
      Quantifies the transcriptional dysregulation asserted by the
      developmental-transcriptional-programs node, and names the enriched
      processes. The typo "deveopment" is present in the source record and is
      reproduced verbatim so the snippet validates.
  notes: >-
    Mouse cortex, not human tissue. No patient-derived transcriptomic dataset
    exists for this disorder, which is the calibration caveat recorded on the
    developmental-transcriptional-programs node.
references:
- reference: PMID:30639322
  title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
- reference: PMID:31879022
  title: "ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder."
- reference: PMID:31833199
  title: "Autosomal dominant inheritance in a recently described ZMIZ1-related neurodevelopmental disorder: Case report of siblings and an affected parent."
- reference: PMID:35432459
  title: "A de Novo ZMIZ1 Pathogenic Variant for Neurodevelopmental Disorder With Dysmorphic Facies and Distal Skeletal Anomalies."
- reference: PMID:38117436
  title: "Clinical report and genetic analysis of a novel variant in ZMIZ1 causing neurodevelopmental disorder with dysmorphic factors and distal skeletal anomalies in a Chinese family."
- reference: PMID:39658964
  title: "A novel ZMIZ1 variant associated with NEDDFSA and new ocular features: case report and review of literature."
- reference: PMID:40529245
  title: "Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder."
- reference: PMID:41354990
  title: "Genetic and functional analysis of ZMIZ1 in neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NEDDFSA): insights from muscle cells and signaling pathways."
- reference: PMID:41039966
  title: "ZMIZ1-Associated Neurodevelopmental Disorder in a 52-Year-Old Woman."
- reference: PMID:41918386
  title: "[A fetus with Neurodevelopmental disorders with deformed facial features and distal skeletal abnormalities due to a rare variant of ZMIZ1 gene and literature review]."
- reference: PMID:41633496
  title: "Loss of Zmiz1 in Mice Leads to Impaired Cortical Development and Autistic-Like Behaviors."
- reference: PMID:38686122
  title: "Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability."
- reference: PMID:35670836
  title: "ZMIZ proteins: partners in transcriptional regulation and risk factors for human disease."
- reference: PMID:34680978
  title: "Compound Heterozygote of Point Mutation and Chromosomal Microdeletion Involving OTUD6B Coinciding with ZMIZ1 Variant in Syndromic Intellectual Disability."

📚

References & Deep Research

References

14

PMID:30639322

ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder.

No top-level findings curated for this source.

PMID:31879022

ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder.

No top-level findings curated for this source.

PMID:31833199

Autosomal dominant inheritance in a recently described ZMIZ1-related neurodevelopmental disorder: Case report of siblings and an affected parent.

No top-level findings curated for this source.

PMID:35432459

A de Novo ZMIZ1 Pathogenic Variant for Neurodevelopmental Disorder With Dysmorphic Facies and Distal Skeletal Anomalies.

No top-level findings curated for this source.

PMID:38117436

Clinical report and genetic analysis of a novel variant in ZMIZ1 causing neurodevelopmental disorder with dysmorphic factors and distal skeletal anomalies in a Chinese family.

No top-level findings curated for this source.

PMID:39658964

A novel ZMIZ1 variant associated with NEDDFSA and new ocular features: case report and review of literature.

No top-level findings curated for this source.

PMID:40529245

Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder.

No top-level findings curated for this source.

PMID:41354990

Genetic and functional analysis of ZMIZ1 in neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NEDDFSA): insights from muscle cells and signaling pathways.

No top-level findings curated for this source.

PMID:41039966

ZMIZ1-Associated Neurodevelopmental Disorder in a 52-Year-Old Woman.

No top-level findings curated for this source.

PMID:41918386

[A fetus with Neurodevelopmental disorders with deformed facial features and distal skeletal abnormalities due to a rare variant of ZMIZ1 gene and literature review].

No top-level findings curated for this source.

PMID:41633496

Loss of Zmiz1 in Mice Leads to Impaired Cortical Development and Autistic-Like Behaviors.

No top-level findings curated for this source.

PMID:38686122

Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability.

No top-level findings curated for this source.

PMID:35670836

ZMIZ proteins: partners in transcriptional regulation and risk factors for human disease.

No top-level findings curated for this source.

PMID:34680978

Compound Heterozygote of Point Mutation and Chromosomal Microdeletion Involving OTUD6B Coinciding with ZMIZ1 Variant in Syndromic Intellectual Disability.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 7 citations 2026-08-15T08:42:38.578115

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Neurodevelopmental Disorder with Dysmorphic Facies and Distal Skeletal Anomalies
MONDO ID: (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Neurodevelopmental Disorder with Dysmorphic Facies and Distal Skeletal Anomalies covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Neurodevelopmental Disorder with Dysmorphic Facies and Distal Skeletal Anomalies

Executive summary

Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NDDFDSA) is an ultra-rare, predominantly de novo autosomal-dominant developmental disorder caused by pathogenic variation affecting ZMIZ1, a transcriptional coregulator associated with chromatin remodeling. The syndrome is characterized principally by developmental delay/intellectual disability, speech and behavioral abnormalities, recognizable facial dysmorphism, and distal limb/skeletal anomalies. Current knowledge comes from small case series, individual case reports, curated disease resources, and experimental models—not population-scale cohorts or EHR studies. Open Targets associates the disease specifically with ZMIZ1 and traces the principal human evidence to Carapito et al., 2019 (PMID 30639322). (OpenTargets Search: Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, c.2024zmiz1isa pages 14-15)

The most important recent development is a 2024 cortex-specific mouse and transcriptomic study. It showed embryonically enriched ZMIZ1 expression, altered cortical neurogenesis and synaptic-gene expression after Zmiz1 deletion, reduced motor-cortex and layer-6 thickness, and increased repetitive behavior. These data support a causal chain from altered transcription/chromatin regulation to defective neuronal differentiation, connectivity, and synaptic signaling. They do not, however, establish a druggable pathway or disease-specific treatment. (c.2024zmiz1isa pages 6-8, c.2024zmiz1isa pages 2-3, c.2024zmiz1isa pages 1-2)

Domain	Established finding	Evidence type/strength	Key identifier or ontology suggestion
Disease identity	Rare Mendelian neurodevelopmental syndrome defined as Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies; disease-target resources link it specifically to ZMIZ1. (OpenTargets Search: Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, c.2024zmiz1isa pages 14-15)	Disease-level curated database association plus foundational primary literature citation	OMIM 618659; EFO_0010659; suggested MONDO label: ZMIZ1-associated neurodevelopmental disorder
Causal gene	Established causal gene is ZMIZ1 (zinc finger MIZ-type containing 1); Open Targets shows this disease associated with ZMIZ1 only. (OpenTargets Search: Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, c.2024zmiz1isa pages 14-15)	Curated disease-gene association supported by human primary literature	ZMIZ1; ENSG00000108175
Inheritance	Reported as a dominant developmental disorder largely driven by de novo pathogenic variants/rearrangements; practical counseling frame is mostly de novo autosomal dominant. (c.2024zmiz1isa pages 1-2, c.2024zmiz1isa pages 14-15)	Human disease literature and review-level synthesis; moderate confidence	Suggested inheritance term: autosomal dominant; HPO inheritance concept validation recommended
Data provenance	Current knowledge is derived from aggregated disease-level resources and small human case reports/series, not EHR-scale cohorts. (OpenTargets Search: Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, c.2024zmiz1isa pages 14-15)	Strong resource-level observation	Evidence source class: rare-disease case-series aggregation
Core phenotype categories	Core manifestations span global neurodevelopmental impairment (ID/developmental delay), behavioral/neuropsychiatric features (including ASD/ADHD-related features), dysmorphic facies, and distal skeletal anomalies; additional reported features may broaden the spectrum. (c.2024zmiz1isa pages 1-2, c.2024zmiz1isa pages 10-11, c.2024zmiz1isa pages 15-16, c.2024zmiz1isa pages 14-15)	Human syndrome reports plus broader 2024 synthesis; moderate confidence because exact frequencies were not extracted	Suggested HPO anchors: Intellectual disability, Global developmental delay, Autistic behavior, Attention deficit hyperactivity disorder, Abnormal facial shape, Skeletal dysplasia/anomaly of the distal limbs
Onset/course	Disorder is best understood as congenital/early-childhood onset neurodevelopmental disease affecting brain development, with persistent developmental and behavioral consequences rather than a remitting course. (c.2024zmiz1isa pages 2-3, c.2024zmiz1isa pages 1-2)	Indirect but strong developmental-biology support plus human phenotype framing	Suggested HPO anchors: Congenital onset, Developmental delay
Molecular function	ZMIZ1 acts as a transcriptional co-regulator/co-activator and chromatin remodeler-associated factor rather than a classic DNA-binding transcription factor. (c.2024zmiz1isa pages 2-3, c.2024zmiz1isa pages 3-6)	Strong mechanistic support from structural/epigenetic analyses and prior literature synthesis	Suggested GO: transcription coregulator activity, chromatin organization, positive regulation of transcription by RNA polymerase II
Structural biology	ZMIZ1 is highly constrained for loss-of-function and is enriched for intrinsically disordered regions and linear interacting peptides, supporting roles in multiprotein complex assembly and regulatory signaling. (c.2024zmiz1isa pages 2-3, c.2024zmiz1isa pages 3-6)	Strong computational/structural evidence integrated with disease interpretation	Suggested annotations: intrinsically disordered protein; protein complex assembly
Chromatin/epigenetic mechanism	ZMIZ1-bound sites are associated with activating histone marks (H3K4me1/2/3, H3K9ac, H3K27ac, H3K79me2) and minimal repressive marks, supporting a model of transcriptional activation/open chromatin regulation. (c.2024zmiz1isa pages 2-3, c.2024zmiz1isa pages 6-8, c.2024zmiz1isa pages 3-6)	Strong mechanistic evidence from public ChIP/epigenomic analyses	Suggested GO: histone modification, chromatin remodeling; CHEBI suggestions: H3K27ac, H3K9ac
Developmental expression	ZMIZ1 is highly expressed in embryonic brain in mouse and human, then decreases postnatally; enrichment is notable in cortex, hippocampus, and cerebellum and in excitatory projection-neuron lineages. (c.2024zmiz1isa pages 1-2, c.2024zmiz1isa pages 2-3)	Strong expression evidence from public transcriptomic atlases	UBERON: cerebral cortex, hippocampus, cerebellum; CL suggestions: cortical projection neuron, excitatory neuron, oligodendrocyte precursor cell, astrocyte, endothelial cell
Pathophysiology	Best-supported causal chain: ZMIZ1 dysfunction → altered chromatin/transcriptional regulation during embryonic brain development → impaired neurogenesis, neuronal differentiation, axon/projection development, and synaptic signaling → neurodevelopmental and behavioral phenotypes. (c.2024zmiz1isa pages 2-3, c.2024zmiz1isa pages 6-8, c.2024zmiz1isa pages 10-11)	Strong multi-layer evidence from mouse transcriptomics and integrated biology; human mechanism remains inferential	Suggested GO: neurogenesis, neuron differentiation, axon development, synaptic signaling, chemical synaptic transmission
Pathway/network context	Interaction/network analyses place ZMIZ1 with NOTCH1, TP53, SMAD3/4, AR, CTNNB1, CNTNAP2, TBR1, SATB1, and other neurodevelopmentally relevant factors; synaptic pathways affected include AMPA receptor activation, GABA signaling, and neurotransmitter release cycle. (c.2024zmiz1isa pages 8-10, c.2024zmiz1isa pages 10-11, c.2024zmiz1isa pages 6-8)	Moderate-to-strong systems-level evidence	Suggested pathway tags: Notch signaling, synaptic signaling, glutamatergic signaling, GABAergic signaling
2024 mouse model findings	Cortex-specific Zmiz1 knockout caused 104 DEGs at P7, reduced motor cortical thickness with significant layer 6 thinning at P3, and increased repetitive behavior in marble-burying assays; synaptic genes such as Gria2, Tnc, Cplx3 were downregulated. (c.2024zmiz1isa pages 6-8, c.2024zmiz1isa pages 8-10, c.2024zmiz1isa pages 11-12)	Strong primary in vivo evidence (mouse) from 2024 study	Model type: conditional mouse knockout; GO/CL suggestions: corticothalamic projection neuron, callosal projection neuron
Diagnostic approach	Diagnosis is primarily molecular, usually by exome/genome sequencing or broad neurodevelopmental disorder testing, with CNV/structural-variant methods relevant because translocations/rearrangements involving ZMIZ1 have also been reported. (c.2024zmiz1isa pages 14-15, c.2024zmiz1isa pages 1-2)	Strong practice inference from gene-discovery context and structural-variant literature	Suggested tests: WES, WGS, trio sequencing, chromosomal microarray, structural variant analysis
Differential diagnosis	Differential diagnosis includes other syndromic intellectual disability/autism disorders with facial and skeletal findings, especially disorders involving transcriptional/chromatin regulators. (c.2024zmiz1isa pages 1-2, c.2024zmiz1isa pages 10-11)	Indirect but reasonable syndrome-level inference	Suggested ontology grouping: syndromic neurodevelopmental disorder
Management	No disease-specific therapy is established; management is supportive and phenotype-directed, including developmental surveillance, speech/occupational/physical therapy, behavioral/psychiatric care, and organ-system evaluation guided by individual findings. (c.2024zmiz1isa pages 10-11, c.2024zmiz1isa pages 11-12)	Standard-of-care inference for rare Mendelian NDDs; limited disease-specific outcome data	NCIT suggestions: Speech Therapy, Occupational Therapy, Physical Therapy, Behavioral Intervention
Prevention/genetic counseling	Primary prevention is not established; after variant identification, families may receive genetic counseling, recurrence-risk assessment, and options for prenatal diagnosis or preimplantation genetic testing. (c.2024zmiz1isa pages 1-2, c.2024zmiz1isa pages 14-15)	Standard Mendelian-genetics practice inference	NCIT suggestions: Genetic Counseling, Prenatal Genetic Testing, Preimplantation Genetic Diagnosis
Epidemiology	Prevalence, incidence, sex ratio, penetrance, expressivity estimates, carrier frequency, and founder effects are not established from currently retrieved evidence. (OpenTargets Search: Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, c.2024zmiz1isa pages 14-15)	Major evidence gap	Evidence-gap flag
Variant-level detail	Exact patient counts, phenotype frequencies, and HGVS-level variant list from the foundational cohort were not available in retrieved full-text evidence and should not be imputed. (OpenTargets Search: Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, c.2024zmiz1isa pages 14-15)	Major evidence gap / inaccessible detailed cohort tabulation	Curation priority: retrieve full Carapito et al. 2019 and later case reports
Treatments/clinical trials	No disease-specific approved targeted therapy or relevant interventional clinical trial was identified in the retrieved searches. (OpenTargets Search: Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies)	Search-based negative finding	Evidence-gap flag; supportive care remains standard

Table: This table summarizes the highest-confidence established facts for ZMIZ1-associated neurodevelopmental disorder, including identity, inheritance, mechanism, model evidence, diagnostics, management, and major evidence gaps. It is designed as a compact curation aid for a disease knowledge base.

1. Disease information

Definition and identifiers

Preferred name: Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies.
Common alternatives: NDDFDSA; ZMIZ1-associated neurodevelopmental disorder; ZMIZ1-related neurodevelopmental disorder; syndromic intellectual disability due to ZMIZ1 variants.
OMIM: #618659.
Open Targets/EFO: EFO_0010659.
Causal-gene identifiers: ZMIZ1, zinc finger MIZ-type containing 1; Ensembl ENSG00000108175; UniProt Q9ULJ6.
MONDO: A definitive MONDO identifier was not recovered in the available evidence; the disease should not be confused with similarly named TRPM3- or RNU4-2-associated disorders. Open Targets returns ZMIZ1 as the sole target for EFO_0010659. (OpenTargets Search: Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies)
Orphanet, MeSH, ICD-10/ICD-11: No disease-specific identifiers were established in the retrieved evidence. Clinically, patients are generally coded under broader intellectual disability, developmental disorder, congenital-anomaly, or genetic-syndrome categories.

The landmark report is Carapito et al., “ZMIZ1 variants cause a syndromic neurodevelopmental disorder,” American Journal of Human Genetics, published 2019, 104:319–330, DOI 10.1016/j.ajhg.2018.12.007, PMID 30639322. (OpenTargets Search: Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, c.2024zmiz1isa pages 14-15)

Data provenance

Evidence is aggregated at disease level from OMIM/Open Targets and from rare-disease case ascertainment, exome/genome sequencing, structural-variant studies, and isolated clinical reports. It is not based on a population registry or longitudinal EHR cohort. The 2024 mechanistic investigation used public human datasets and a conditional mouse model; it did not recruit a new human cohort. (c.2024zmiz1isa pages 1-2, c.2024zmiz1isa pages 14-15)

2. Etiology

Causal factors and genetic risk

The primary cause is germline disruption of ZMIZ1 by pathogenic coding variants, regulatory variants, or chromosomal rearrangements affecting the gene or its regulatory context. Most reported disease-associated variants are de novo, supporting autosomal-dominant inheritance. ZMIZ1 is highly constrained against loss-of-function variation: only 7 loss-of-function variants were observed versus 52.1 expected in the referenced dataset, corresponding to an observed/expected ratio of 0.13. Missense constraint was less extreme but still evident (447 observed versus 699.1 expected; ratio 0.64). (c.2024zmiz1isa pages 2-3)

Disease-associated single-nucleotide variants are distributed across the protein but cluster in the TPR, alanine-rich, central proline-rich, and C-terminal proline-rich domains. The 2024 analysis estimated that 65% of disease-causing SNVs occurred in those regions; normalized by domain length, the alanine-rich region had the largest reported mutation burden. This is computational/domain-level evidence, not a validated genotype–phenotype rule. (c.2024zmiz1isa pages 3-6)

Balanced chromosomal rearrangements may disrupt ZMIZ1 directly or produce position effects, so pathogenicity is not restricted to SNVs or small indels. This supports genome/structural-variant analysis where exome testing is negative. (c.2024zmiz1isa pages 14-15)

Environmental, infectious, and lifestyle risk

No environmental toxin, infection, diet, lifestyle, occupational exposure, parental-age effect, or sex-specific risk has been established for NDDFDSA. Environmental factors can affect neurodevelopment generally, but none should be entered as a disease-specific causal factor without further evidence.

Protective factors and gene–environment interaction

No protective alleles, modifier genes, preventive exposures, or demonstrated gene–environment interactions are known. ZMIZ1 has broader associations with immune regulation and vitamin-D-responsive biology, but these observations concern other phenotypes and do not establish vitamin D or immune exposure as a modifier of NDDFDSA. (c.2024zmiz1isa pages 15-16)

3. Phenotypes

Core phenotype framework

The directly supported phenotype spectrum includes developmental delay/intellectual impairment, speech-development delay, motor impairment, autism-related or social-communication deficits, repetitive or other behavioral abnormalities, dysmorphic facial features, and distal skeletal abnormalities. Seizures have been described among the broader human phenotypes cited by the 2024 study, but exact disease-specific frequency was not recoverable. (c.2024zmiz1isa pages 10-11)

Suggested knowledge-base mappings are:

Phenotype category	Type, onset, course, and functional effect	Suggested HPO terms
Developmental delay/intellectual disability	Developmental sign; apparent in infancy or childhood; severity and expressivity variable; generally persistent and lifelong. Affects learning, independence, and adaptive function.	Global developmental delay HP:0001263; Intellectual disability HP:0001249
Speech/language delay	Developmental symptom, generally early childhood; can materially impair communication and education.	Delayed speech and language development HP:0000750
Autism/social-communication abnormalities	Behavioral phenotype; childhood onset; variable severity and persistence.	Autistic behavior HP:0000729; Abnormal social behavior HP:0012433
Attention/hyperactivity or aggression/anxiety	Behavioral changes; variably reported rather than obligatory.	Attention deficit hyperactivity disorder HP:0007018; Aggressive behavior HP:0000718; Anxiety HP:0000739
Motor delay or impaired motor function	Developmental sign; may affect mobility and daily activities.	Motor delay HP:0001270; Abnormality of movement HP:0100022
Seizures	Neurologic sign reported in the broader spectrum; frequency, type, and prognosis not established.	Seizure HP:0001250
Facial dysmorphism	Congenital physical manifestation; specific combinations vary among individuals.	Abnormal facial shape HP:0001999; individual facial HPO terms should be curated patient by patient
Distal skeletal/limb anomalies	Congenital physical findings involving hands, fingers, feet, or toes; generally structural and stable.	Abnormality of the hand HP:0001155; Abnormality of the foot HP:0001760; Abnormality of the digits HP:0011297
Hirschsprung disease	Reported in a 2021 patient with a de novo pathogenic ZMIZ1 variant; possible spectrum expansion, not an established common feature.	Hirschsprung disease HP:0002251

The 2021 Hirschsprung case is Valind et al., Journal of Pediatric Surgery Case Reports 71:101889, DOI 10.1016/j.epsc.2021.101889. The 2024 authors state: “a case study revealed a de novo pathogenic variant in ZMIZ1 in a patient with developmental delay and Hirschsprung Disease.” (c.2024zmiz1isa pages 10-11, c.2024zmiz1isa pages 15-16)

Frequencies and quality of life

Reliable percentages for individual clinical features could not be extracted from the available foundational full text. Frequencies should therefore remain unknown, not be estimated from the syndrome name or from secondary summaries. No EQ-5D, SF-36, PROMIS, disease-specific quality-of-life instrument, or formal caregiver-burden study was identified. Functional burden is nevertheless expected from impaired cognition, communication, behavior, and motor development.

4. Genetic and molecular information

Gene and protein

ZMIZ1 encodes a PIAS-like transcriptional coregulator, also called Zimp10. The protein is unusually disordered: the 2024 analysis classified approximately 66.4% as intrinsically disordered and 50.3% as linear interacting peptides, whereas about 22.3% comprised structured functional domains. These properties are consistent with multiprotein-complex formation, transcriptional regulation, and potentially phase-separated regulatory assemblies. (c.2024zmiz1isa pages 3-6)

Variant spectrum and classification

Reported disease mechanisms encompass de novo missense and other coding variants, regulatory-region variation, direct gene disruption, and chromosomal position effects. Exact HGVS variants and patient-level ACMG classifications from the foundational cohort were unavailable in the retrieved text and should be obtained directly from PMID 30639322 and current ClinVar records before variant-level database ingestion. (c.2024zmiz1isa pages 2-3, c.2024zmiz1isa pages 14-15)

The variants are germline in the congenital syndrome. Somatic ZMIZ1 alterations are relevant to cancer biology but are not causal evidence for NDDFDSA. Population allele frequencies for individual pathogenic variants were not recovered; pathogenic de novo variants would generally be expected to be absent or exceptionally rare in reference populations, but each variant requires direct gnomAD/ClinVar verification.

Functional consequence

The most coherent current model is altered dosage or function of a transcriptional coactivator, producing dysregulated developmental gene expression. Although haploinsufficiency/functional loss is strongly supported by gene constraint and knockout phenotypes, not every missense allele has been experimentally proven to act through simple loss of function. Dominant-negative or allele-specific effects therefore remain possible for some variants.

Modifier genes, chromosomal abnormalities, and epigenetics

No validated modifier gene is known. Candidate interacting proteins include NOTCH1, TP53, SMAD3/4, androgen receptor, CTNNB1, CNTNAP2, SATB1, TBR1, HDAC1, BRCA1, and SWI/SNF/BAF components SMARCA4 and SMARCE1. These are interaction/network candidates, not proven clinical modifiers. (c.2024zmiz1isa pages 8-10, c.2024zmiz1isa pages 10-11)

At ZMIZ1-bound sites, activating marks H3K4me1/2/3, H3K9ac, H3K27ac, and H3K79me2 were enriched, while H3K9me3 and H3K27me3 were minimal in K562 ENCODE-derived analyses. This supports coactivator/open-chromatin function but is not a disease-specific patient methylation signature. (c.2024zmiz1isa pages 6-8, c.2024zmiz1isa pages 3-6)

5. Environmental information

No disease-specific environmental, lifestyle, infectious, nutritional, radiation, or occupational determinant has been demonstrated. Smoking, alcohol, diet, and exercise have no established role in causing or preventing this monogenic congenital disorder. Standard avoidance of teratogens remains general prenatal care rather than NDDFDSA-specific prevention.

6. Mechanism and pathophysiology

Causal chain

A pathogenic germline ZMIZ1 variant or structural disruption alters ZMIZ1 dosage/function.
The defect perturbs transcriptional coregulation and chromatin-associated developmental programs during embryogenesis.
Neurogenesis, neuronal differentiation, axon/projection morphogenesis, and synaptic-gene expression become dysregulated.
Cortical architecture and excitatory/inhibitory circuit development are altered.
These upstream developmental changes plausibly produce intellectual, language, motor, autistic/behavioral, and seizure phenotypes. Parallel effects in craniofacial and distal skeletal developmental programs likely produce dysmorphism and limb anomalies, although the skeletal causal chain is much less experimentally resolved. (c.2024zmiz1isa pages 6-8, c.2024zmiz1isa pages 2-3)

Recent transcriptomic and pathway evidence

In cortex-specific Zmiz1-knockout mice, P7 RNA sequencing identified 104 differentially expressed genes, including 35 downregulated and 69 upregulated genes. Sixteen overlapped SFARI autism-risk genes, including ABAT, AHI1, CACNA2D1, CACNA2D3, CUX2, DPYSL2, GRIA1, GRIA2, RORB, SATB1, SATB2, SLC6A1, TAOK1, TCF4, and ZMIZ1. Twenty-six DEGs mapped to SynGO genes. Enriched processes included neurogenesis, neuron differentiation, axon development, neuron-projection morphogenesis, synapse organization, neurotransmitter release, AMPA-receptor activation, chemical synaptic transmission, and GABA signaling. (c.2024zmiz1isa pages 8-10, c.2024zmiz1isa pages 6-8)

The authors directly reported that “Biological processes such as neurogenesis, neuron development and differentiation, axon development, and neuron projection morphogenesis were significantly affected in the Zmiz1-KO cortex.” They also found downregulation of Gria2, Tnc, and Cplx3 by qPCR. (c.2024zmiz1isa pages 10-11, c.2024zmiz1isa pages 6-8)

Cell and tissue context

ZMIZ1 expression peaks during mouse embryonic days E12–E18 and declines postnatally; human brain data show a comparable prenatal enrichment. Expression is highest in cortex and cerebellum and is also prominent in hippocampus. It occurs in neurons, endothelial cells, pericytes, astrocytes, Bergmann glia, oligodendrocytes, and oligodendrocyte precursor cells, with stronger expression in excitatory than GABAergic neurons. Cortical ventricular/subventricular progenitors and callosal and corticothalamic projection-neuron lineages are particularly relevant. (c.2024zmiz1isa pages 2-3, c.2024zmiz1isa pages 1-2)

Suggested ontology terms include:

GO biological process: neurogenesis GO:0022008; neuron differentiation GO:0030182; axon development GO:0061564; synaptic signaling GO:0099536; chemical synaptic transmission GO:0007268; chromatin organization GO:0006325.
GO cellular component: nucleus GO:0005634; chromatin GO:0000785; axon GO:0030424; dendrite GO:0030425; synapse GO:0045202; postsynaptic membrane GO:0045211.
Cell Ontology suggestions: neural progenitor cell; excitatory neuron; glutamatergic neuron; GABAergic neuron; cortical projection neuron; corticothalamic projection neuron; callosal projection neuron; astrocyte; oligodendrocyte; oligodendrocyte precursor cell; endothelial cell; pericyte. Exact CL identifiers should be validated against the release used by the knowledge base.

Omics and advanced technologies

The principal disease-relevant profiling consists of bulk cortical RNA-seq, qPCR, public developmental and single-cell transcriptomic atlases, Ribo-seq, interaction-network analysis, and ENCODE-derived chromatin analysis. The P7 cortex data are deposited under GEO GSE225435. No disease-specific patient proteomic, metabolomic, lipidomic, spatial-transcriptomic, or integrated multi-omic signature has been established. Human patient-derived iPSC and organoid studies were proposed as future work rather than reported as completed disease models. (c.2024zmiz1isa pages 11-12, c.2024zmiz1isa pages 12-14)

7. Anatomical structures affected

The central nervous system is the principal functional system, especially cerebral cortex, hippocampus, cerebellum, developing cortical plate, and neuronal axon/dendrite/synapse compartments. Craniofacial structures and distal appendicular skeleton are clinically affected. Possible enteric nervous-system involvement is suggested by Hirschsprung disease in one case. (c.2024zmiz1isa pages 10-11, c.2024zmiz1isa pages 2-3)

Suggested UBERON mappings are cerebral cortex UBERON:0000956, hippocampus UBERON:0002421, cerebellum UBERON:0002037, brain UBERON:0000955, hand UBERON:0002398, foot UBERON:0002387, and enteric nervous system UBERON:0002005. Distal skeletal findings may be bilateral or asymmetric depending on the anomaly; no consistent lateralization is established.

8. Temporal development

NDDFDSA is a congenital developmental disorder, although developmental and behavioral manifestations become evident progressively during infancy and childhood as milestones are assessed. The expression peak during embryonic brain development identifies prenatal neurogenesis and circuit formation as critical vulnerability periods. (c.2024zmiz1isa pages 2-3, c.2024zmiz1isa pages 1-2)

No formal staging system exists. Structural dysmorphism and skeletal anomalies are generally stable, whereas developmental demands may make cognitive, language, and behavioral impairments more apparent with age. The condition is expected to be lifelong; episodic remission or spontaneous recovery has not been documented. Longitudinal natural-history data are insufficient to determine whether any neurologic component is degenerative.

9. Inheritance and population

The inheritance model is autosomal dominant, usually de novo. Variable expressivity is evident from the breadth of developmental, behavioral, skeletal, and occasional additional-organ findings. Penetrance has not been quantified. Parental germline mosaicism remains a theoretical recurrence mechanism for apparently de novo variants, as in other dominant developmental disorders, but a disease-specific mosaicism rate is unknown.

No prevalence, incidence, carrier frequency, founder variant, anticipation, population enrichment, geographic clustering, consanguinity effect, sex ratio, or age distribution has been established. The disorder is ultra-rare and ascertainment is likely limited by recent recognition and use of broad genomic testing. Open Targets identifies only five evidence records, all linked to the same foundational PMID, illustrating the limited independent evidence base rather than disease prevalence. (OpenTargets Search: Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies)

10. Diagnostics

Recommended molecular strategy

Trio WES or WGS is the preferred first-line approach for unexplained syndromic developmental delay/intellectual disability, especially with facial and distal skeletal findings.
Ensure analysis includes ZMIZ1 coding variants, splice variants, de novo calling, and copy-number detection.
WGS has added value for regulatory variants, balanced rearrangements, and position effects.
Use chromosomal microarray for deletions/duplications, while recognizing that CMA will not detect most balanced rearrangements.
Consider karyotyping, genome sequencing, or targeted breakpoint analysis when a balanced translocation/inversion is suspected.
Confirm candidate variants and parental status by an orthogonal method; classify under current ACMG/AMP criteria.

No biochemical assay, circulating biomarker, biopsy, or pathognomonic imaging signature exists. Laboratory, EEG, MRI, ophthalmologic, gastrointestinal, and skeletal imaging should be directed by symptoms. Genetic testing, rather than facial gestalt alone, is required for confirmation. The 2024 authors explicitly proposed that “ZMIZ1 mutation testing may aid in identifying ASD risk, enabling early diagnosis,” but this is an expert research recommendation rather than a validated screening guideline. (c.2024zmiz1isa pages 10-11, c.2024zmiz1isa pages 11-12)

Differential diagnosis

Important differentials include other syndromic neurodevelopmental disorders with facial and distal limb abnormalities, including chromatin/transcription-regulator disorders, TRPM3-related neurodevelopmental disorder with hypotonia and skeletal anomalies, Coffin–Siris spectrum disorders, KBG syndrome, Kabuki syndrome, Wiedemann–Steiner syndrome, Cornelia de Lange spectrum, and pathogenic CNVs. Distinguishing features require full phenotyping and molecular testing; similar disease names should not be treated as synonyms.

Screening

NDDFDSA is not part of routine newborn screening. Cascade testing is appropriate after identifying a familial variant. Population carrier screening is not indicated for a disorder that is predominantly de novo dominant.

11. Outcome and prognosis

No survival curves, mortality rates, life-expectancy estimates, or validated prognostic biomarkers are available. The available literature does not indicate an intrinsically fatal or degenerative syndrome, but the evidence base is too small to establish normal life expectancy.

Long-term morbidity is likely driven by intellectual and language impairment, behavioral/psychiatric manifestations, motor limitations, seizures where present, and orthopedic or gastrointestinal complications. Prognosis should therefore be individualized according to developmental severity, communication ability, seizure control, mobility, feeding, and organ involvement. No formal quality-of-life or recovery-rate data exist.

12. Treatment

There is no approved disease-modifying pharmacotherapy, gene therapy, RNA therapy, cell therapy, or ZMIZ1-targeted treatment. No disease-specific interventional ClinicalTrials.gov study was identified.

Current management is multidisciplinary and phenotype directed:

Early developmental intervention and individualized education.
Speech/language therapy, including augmentative communication where needed.
Occupational and physical therapy for adaptive and motor impairment.
Behavioral therapy and child psychiatry for autism, ADHD, anxiety, aggression, or sleep disturbance.
Standard antiseizure treatment if epilepsy occurs.
Orthopedic/podiatric assessment for functionally important distal skeletal anomalies.
Feeding, nutrition, hearing, vision, and gastrointestinal evaluation as clinically indicated.
Surgical management for Hirschsprung disease or another congenital anomaly when present.

Suggested NCIT concepts include Physical Therapy, Occupational Therapy, Speech Therapy, Behavior Therapy, Anticonvulsant Therapy, Orthopedic Surgery, and Genetic Counseling; exact NCIT codes should be validated against the target terminology release.

The 2024 study does not justify direct clinical targeting of AMPA, GABA, NOTCH, p53, or chromatin pathways. Its authors conclude that further animal, iPSC, organoid, and gene-regulatory-network studies are needed before therapeutic approaches can be defined. (c.2024zmiz1isa pages 10-11, c.2024zmiz1isa pages 11-12)

13. Prevention

Primary prevention through lifestyle modification, vaccination, environmental remediation, or prophylactic medication is not applicable. Secondary prevention consists of early molecular diagnosis and prompt developmental intervention. Tertiary prevention involves seizure management, rehabilitation, behavioral support, orthopedic care, and surveillance for individual complications.

Genetic counseling should explain the predominantly de novo dominant mechanism, the low but nonzero recurrence possibility from parental germline mosaicism, and the 50% transmission risk for an affected individual with a heterozygous pathogenic variant, subject to penetrance and reproductive fitness. Once a familial pathogenic variant is known, prenatal diagnosis and preimplantation genetic testing are technically possible. These are reproductive options, not treatments for an affected fetus or child.

14. Other species and natural disease

No naturally occurring ZMIZ1-associated veterinary syndrome homologous to human NDDFDSA was identified. There is no zoonotic or cross-species transmission because this is a germline genetic disorder.

Relevant orthologs include mouse Zmiz1 (Mus musculus, NCBI Taxonomy 10090) and zebrafish zmiz1 ortholog(s) (Danio rerio, Taxonomy 7955). ZMIZ1’s developmental expression and essential vascular functions are evolutionarily conserved, but these are experimental observations rather than documented natural animal disease. Whole-body Zmiz1 loss in mice is associated with embryonic viability and vascular-development defects. (c.2024zmiz1isa pages 14-15)

15. Model organisms

Cortex-specific mouse model

The strongest disease-relevant model is an Emx1-Cre conditional Zmiz1 knockout targeting cortical progenitors. At P3, knockout mice had significantly reduced motor-cortex thickness and significant layer-6 thinning; developing upper layers showed a nonsignificant reduction trend, while layer 5 was not significantly altered. Adult knockout mice displayed increased repetitive behavior in a marble-burying assay. P7 cortex showed 104 DEGs and altered neurodevelopmental and synaptic pathways. (c.2024zmiz1isa pages 6-8, c.2024zmiz1isa pages 3-6)

This model recapitulates selected human domains—abnormal cortical development and repetitive behavior—but does not reproduce the full facial, distal skeletal, language, or intellectual phenotype. It is therefore best suited to studying cortical neurogenesis, projection-neuron development, synaptic networks, and candidate molecular interventions, not whole-syndrome severity.

Other models and resources

Conventional/vascular mouse models: useful for embryonic viability, angiogenesis, and pleiotropic ZMIZ1 function but less specific to NDDFDSA neurobehavioral pathology.
Cellular systems: public human and mouse expression datasets, K562 ChIP-derived chromatin profiles, and neuronal transcriptome/translatome datasets have been used; no validated patient-derived cellular diagnostic model exists.
Future systems: patient-derived iPSCs, cortical organoids, and variant-specific knock-in models were recommended to determine allele-specific effects and therapeutic reversibility. (c.2024zmiz1isa pages 1-2, c.2024zmiz1isa pages 11-12)
Resources: Jackson Laboratory Emx1-Cre stock 005628; study transcriptome GEO GSE225435. (c.2024zmiz1isa pages 11-12)

Evidence assessment and curation priorities

The strongest human causal evidence remains the 2019 case series (PMID 30639322), while the strongest current mechanistic evidence is Rajan et al., published 15 April 2024, Frontiers in Psychiatry 15:1375492, DOI 10.3389/fpsyt.2024.1375492. Its abstract states: “Our analysis reveals that Zmiz1 regulates multiple developmental processes, including neurogenesis, neuron connectivity, and synaptic signaling.” (c.2024zmiz1isa pages 1-2)

Priority gaps are: (1) a complete current ClinVar/HGVS variant inventory; (2) exact phenotype frequencies from the foundational and subsequent cohorts; (3) longitudinal natural history; (4) penetrance and recurrence estimates; (5) patient-derived functional studies; (6) rigorous craniofacial and skeletal mechanisms; and (7) disease-specific treatment trials. Until those gaps are filled, quantitative frequencies, genotype–phenotype correlations, and prognosis should be recorded as unknown rather than inferred from related neurodevelopmental disorders.

References

(OpenTargets Search: Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies): Open Targets Query (Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(c.2024zmiz1isa pages 14-15): Rajan K. C., Alina S. Tiemroth, Abbigail N. Thurmon, Stryder M. Meadows, and Maria J. Galazo. Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability. Frontiers in Psychiatry, Apr 2024. URL: https://doi.org/10.3389/fpsyt.2024.1375492, doi:10.3389/fpsyt.2024.1375492. This article has 12 citations.
(c.2024zmiz1isa pages 6-8): Rajan K. C., Alina S. Tiemroth, Abbigail N. Thurmon, Stryder M. Meadows, and Maria J. Galazo. Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability. Frontiers in Psychiatry, Apr 2024. URL: https://doi.org/10.3389/fpsyt.2024.1375492, doi:10.3389/fpsyt.2024.1375492. This article has 12 citations.
(c.2024zmiz1isa pages 2-3): Rajan K. C., Alina S. Tiemroth, Abbigail N. Thurmon, Stryder M. Meadows, and Maria J. Galazo. Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability. Frontiers in Psychiatry, Apr 2024. URL: https://doi.org/10.3389/fpsyt.2024.1375492, doi:10.3389/fpsyt.2024.1375492. This article has 12 citations.
(c.2024zmiz1isa pages 1-2): Rajan K. C., Alina S. Tiemroth, Abbigail N. Thurmon, Stryder M. Meadows, and Maria J. Galazo. Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability. Frontiers in Psychiatry, Apr 2024. URL: https://doi.org/10.3389/fpsyt.2024.1375492, doi:10.3389/fpsyt.2024.1375492. This article has 12 citations.
(c.2024zmiz1isa pages 10-11): Rajan K. C., Alina S. Tiemroth, Abbigail N. Thurmon, Stryder M. Meadows, and Maria J. Galazo. Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability. Frontiers in Psychiatry, Apr 2024. URL: https://doi.org/10.3389/fpsyt.2024.1375492, doi:10.3389/fpsyt.2024.1375492. This article has 12 citations.
(c.2024zmiz1isa pages 15-16): Rajan K. C., Alina S. Tiemroth, Abbigail N. Thurmon, Stryder M. Meadows, and Maria J. Galazo. Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability. Frontiers in Psychiatry, Apr 2024. URL: https://doi.org/10.3389/fpsyt.2024.1375492, doi:10.3389/fpsyt.2024.1375492. This article has 12 citations.
(c.2024zmiz1isa pages 3-6): Rajan K. C., Alina S. Tiemroth, Abbigail N. Thurmon, Stryder M. Meadows, and Maria J. Galazo. Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability. Frontiers in Psychiatry, Apr 2024. URL: https://doi.org/10.3389/fpsyt.2024.1375492, doi:10.3389/fpsyt.2024.1375492. This article has 12 citations.
(c.2024zmiz1isa pages 8-10): Rajan K. C., Alina S. Tiemroth, Abbigail N. Thurmon, Stryder M. Meadows, and Maria J. Galazo. Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability. Frontiers in Psychiatry, Apr 2024. URL: https://doi.org/10.3389/fpsyt.2024.1375492, doi:10.3389/fpsyt.2024.1375492. This article has 12 citations.
(c.2024zmiz1isa pages 11-12): Rajan K. C., Alina S. Tiemroth, Abbigail N. Thurmon, Stryder M. Meadows, and Maria J. Galazo. Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability. Frontiers in Psychiatry, Apr 2024. URL: https://doi.org/10.3389/fpsyt.2024.1375492, doi:10.3389/fpsyt.2024.1375492. This article has 12 citations.
(c.2024zmiz1isa pages 12-14): Rajan K. C., Alina S. Tiemroth, Abbigail N. Thurmon, Stryder M. Meadows, and Maria J. Galazo. Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability. Frontiers in Psychiatry, Apr 2024. URL: https://doi.org/10.3389/fpsyt.2024.1375492, doi:10.3389/fpsyt.2024.1375492. This article has 12 citations.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	5
Resolved	5
Unresolved (possible confabulation)	0
Unverifiable	0

All extracted references resolved successfully.

Ask OpenScientist

OpenScientist Report

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Variants

Medical Actions

Diagnosis

Prevalence

Differential Diagnoses

Related Datasets

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Neurodevelopmental Disorder with Dysmorphic Facies and Distal Skeletal Anomalies

Executive summary

1. Disease information

Definition and identifiers

Data provenance

2. Etiology

Causal factors and genetic risk

Environmental, infectious, and lifestyle risk

Protective factors and gene–environment interaction

3. Phenotypes

Core phenotype framework

Frequencies and quality of life

4. Genetic and molecular information

Gene and protein

Variant spectrum and classification

Functional consequence

Modifier genes, chromosomal abnormalities, and epigenetics

5. Environmental information

6. Mechanism and pathophysiology

Causal chain

Recent transcriptomic and pathway evidence

Cell and tissue context

Omics and advanced technologies

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Recommended molecular strategy

Differential diagnosis

Screening

11. Outcome and prognosis

12. Treatment

13. Prevention

14. Other species and natural disease

15. Model organisms

Cortex-specific mouse model

Other models and resources

Evidence assessment and curation priorities

Artifacts

Reference Validation